Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

  • Rivera-Esteban, Jesús
  • Manzano-Nuñez, Ramiro
  • Broquetas, Teresa
  • Serra-Matamala, Isabel
  • Bassegoda, Octavi
  • Soriano-Varela, Agnès
  • Espín, Gemma
  • Castillo, Joaquín
  • Bañares, Juan
  • Carrión Rodríguez, José Antonio
  • Ginès, Pere
  • Graupera, Isabel
  • Pericàs, Juan
Background & aims: The COVID-19 pandemic has had a major negative impact on health systems and many chronic diseases globally. We aimed to evaluate the impact of the first year of the pandemic on the outcomes of people with NAFLD cirrhosis. Methods: We conducted a before-after study in four University hospitals in Catalonia, Spain. Study subperiods were divided into Pre-pandemic (March/2019-February/2020) vs. Pandemic (March/2020-February/2021). The primary outcome was the rate of first liver-related event (LRE). Overall clinical outcomes (LREs plus cardiovascular plus all-cause mortality) were also assessed. Results: A total of 354 patients were included, all of whom were compensated at the beginning of the study period; 83 individuals (23.5%) had a history of prior hepatic decompensation. Mean age was 67.3 years and 48.3% were female. Median BMI was 31.2 kg/m2 and type 2 diabetes was present in 72.8% of patients. The rates of first LRE in the Pre-pandemic and Pandemic periods were 7.4% and 11.3% (p = 0.12), respectively. Whilst the rate of overall events was significantly higher in the Pandemic period (9.9% vs. 17.8%; p = 0.009), this was strongly associated with COVID-19-related deaths. The rate of worsened metabolic status was significantly higher in the Pandemic period (38.4% vs. 46.1%; p = 0.041), yet this was not associated with the risk of first LRE during the Pandemic period, whereas type 2 diabetes (odds ratio [OR] 3.77; 95% CI 1.15-12.32; p = 0.028), albumin <4 g/L (OR 4.43; 95% CI 1.76-11.17; p = 0.002) and Fibrosis-4 score >2.67 (OR 15.74; 95% CI 2.01-123.22; p = 0.009) were identified as risk factors in the multivariable analysis. Conclusion: Overall, people with NAFLD cirrhosis did not present poorer liver-related outcomes during the first year of the pandemic. Health system preparedness seems key to ensure that people with NAFLD cirrhosis receive appropriate care during health crises.Lay summary: Mobility restrictions and social stress induced by the COVID-19 pandemic have led to increased alcohol drinking and worsened metabolic control (e.g., weight gain, poor control of diabetes) in a large proportion of the population in many countries. We aimed to analyze whether people with cirrhosis due to non-alcoholic fatty liver disease, who are particularly vulnerable to such lifestyle modifications, were significantly impacted during the first year of the pandemic. We compared the clinical situation of 354 patients one year before the pandemic and one year after. We found that although metabolic control was indeed worse after the first year of the pandemic and patients presented worse clinical outcomes, the latter was mostly due to non-liver causes, namely COVID-19 itself. Moreover, the care provided to these patients did not worsen during the first year of the pandemic., TB has received educational and research support from Gilead and Abbvie. JMP reports having received consulting fees from Boehringer Ingelheim and Novo Nordisk. He has received speaking fees from Gilead, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD, and funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. Other authors: nothing to disclose. None of the authors have any personal conflict with regards to the present manuscript.
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

  • Nakanishi, Tomoko
  • Martínez Bueno, Manuel|||0000-0002-1488-5642
  • García García, Federico
  • Alarcón Riquelme, Marta Eugenia
  • FinnGen
  • The COVID-19 Host Genetics Initiative
AG has received support by NordForsk Nordic Trial Alliance (NTA) grant, by Academy of Finland Fellow grant N. 323116 and the Academy of Finland for PREDICT consortium N. 340541. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Québec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS). TN is supported by a research fellowship of the Japan Society for the Promotion of Science for Young Scientists. GBL is supported by a CIHR scholarship and a joint FRQS and Québec Ministry of Health and Social Services scholarship. JBR is supported by an FRQS Clinical Research Scholarship. Support from Calcul Québec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, the Medical Research Council, the European Union, the National Institute for Health Research-funded BioResource and the Clinical Research Facility and Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust in partnership with King’s College London. The Biobanque Québec COVID19 is funded by FRQS, Genome Québec and the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé. These funding agencies had no role in the design, implementation or interpretation of this study. The COVID19-Host(a)ge study received infrastructure support from the DFG Cluster of Excellence 2167 “Precision Medicine in Chronic Inflammation (PMI)” (DFG Grant: “EXC2167”). The COVID19-Host(a)ge study was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). Genotyping in COVID19-Host(a)ge was supported by a philantropic donation from Stein Erik Hagen. The COVID GWAs, Premed COVID-19 study (COVID19-Host(a)ge_3) was supported by "Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia"and also by the Instituto de Salud Carlos III (CIBERehd and CIBERER). Funding comes from COVID-19-GWAS, COVID-PREMED initiatives. Both of them are supported by "Consejeria de Salud y Familias" of the Andalusian Government. DMM is currently funded by the the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018). The Columbia University Biobank was supported by Columbia University and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Columbia University. The SPGRX study was supported by the Consejería de Economía, Conocimiento, Empresas y Universidad #CV20-10150. The GEN-COVID study was funded by: the MIUR grant “Dipartimenti di Eccellenza 2018-2020” to the Department of Medical Biotechnologies University of Siena, Italy; the “Intesa San Paolo 2020 charity fund” dedicated to the project NB/2020/0119; and philanthropic donations to the Department of Medical Biotechnologies, University of Siena for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). Part of this research project is also funded by Tuscany Region “Bando Ricerca COVID-19 Toscana” grant to the Azienda Ospedaliero Universitaria Senese (CUP I49C20000280002). Authors are grateful to: the CINECA consortium for providing computational resources; the Network for Italian Genomes (NIG) (http://www.nig.cineca.it) for its support; the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/); the Genetic Biobank of Siena, member of BBMRI-IT, Telethon Network of Genetic Biobanks (project no. GTB18001), EuroBioBank, and RD-Connect, for managing specimens. Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was supported by Ricerca Corrente (Italian Ministry of Health), intramural funding (Fondazione Humanitas per la Ricerca). The generous contribution of Banca Intesa San Paolo and of the Dolce&Gabbana Fashion Firm is gratefully acknowledged. Data acquisition and sample processing was supported by COVID-19 Biobank, Fondazione IRCCS Cà Granda Milano; LV group was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- “Liver Investigation: Testing Marker Utility in Steatohepatitis”, Programme “Photonics” under grant agreement “101016726” for the project “REVEAL: Neuronal microscopy for cell behavioural examination and manipulation”, Fondazione Patrimonio Ca’ Granda “Liver Bible” PR-0361. DP was supported by Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, CV PREVITAL “Strategie di prevenzione primaria nella popolazione Italiana” Ministero della Salute, and Associazione Italiana per la Prevenzione dell’Epatite Virale (COPEV). Genetic modifiers for COVID-19 related illness (BeLCovid_1) was supported by the "Fonds Erasme". The Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2) study was supported by grants from Fondation Léon Fredericq and from Fonds de la Recherche Scientifique (FNRS). The INMUNGEN-CoV2 study was funded by the Consejo Superior de Investigaciones Científicas. KUL is supported by the German Research Foundation (LU 1944/3-1) SweCovid is funded by the SciLifeLab/KAW national COVID-19 research program project grant to Michael Hultström (KAW 2020.0182) and the Swedish Research Council to Robert Frithiof (2014-02569 and 2014-07606). HZ is supported by Jeansson Stiftelser, Magnus Bergvalls Stiftelse. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. Genotyping for the COMRI cohort was performed and funded by the Genotyping Laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Helsinki, Finland. These funding agencies had no role in the design, implementation or interpretation of this study., Background: There is considerable variability in COVID-19 outcomes amongst younger adults—and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. Method: The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. Findings: We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. Interpretation: The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality—and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management., Academy of Finland Fellow grant N. 323116, Academy of Finland for PREDICT consortium N. 340541., Canadian Institutes of Health Research (CIHR) (365825 and 409511), Lady Davis Institute of the Jewish General Hospital, Canadian Foundation for Innovation (CFI), NIH Foundation, Cancer Research UK, Genome Québec, Public Health Agency of Canada, McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Québec Santé (FRQS), Japan Society for the Promotion of Science for Young Scientists, CIHR scholarship and a joint FRQS and Québec Ministry of Health and Social Services scholarship, FRQS Clinical Research Scholarship, Calcul Québec, Compute Canada, Welcome Trust, Medical Research Counc, European Union, National Institute for Health Research-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s and St. Thomas’ NHS Foundation Trust, King’s College London, Genome Québec, Public Health Agency of Canada, McGill Interdisciplinary Initiative in Infection and Immunity, Fonds de Recherche Québec Santé, (DFG Grant: “EXC2167”), (CompLS grant 031L0165), Stein Erik Hagen, "Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia", Instituto de Salud Carlos III (CIBERehd and CIBERER), COVID-19-GWAS, COVID-PREMED initiatives, "Consejeria de Salud y Familias" of the Andalusian Government, Andalusian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018), Columbia University, National Center for Advancing Translational Sciences, NIH Grant Number UL1TR001873, Consejería de Economía, Conocimiento, Empresas y Universidad #CV20-10150, MIUR grant “Dipartimenti di Eccellenza 2018-2020”, “Intesa San Paolo 2020 charity fund” dedicated to the project NB/2020/0119, Tuscany Region “Bando Ricerca COVID-19 Toscana”, CINECA consortium, Network for Italian Genomes (NIG), COVID-19 Host Genetics Initiative, Genetic Biobank of Siena, EuroBioBank, RD-Connect, Ricerca Corrente (Italian Ministry of Health), Fondazione Humanitas per la Ricerca, Banca Intesa San Paolo, Dolce&Gabbana Fashion Firm, COVID-19 Biobank, Fondazione IRCCS Cà Granda Milano, MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377), “Photonics” “101016726”, Fondazione Patrimonio Ca’ Granda “Liver Bible” PR-0361, CV PREVITAL “Strategie di prevenzione primaria nella popolazione Italiana” Ministero della Salute, and Associazione Italiana per la Prevenzione dell’Epatite Virale (COPEV), "Fonds Erasme", Fondation Léon Fredericq, Fonds de la Recherche Scientifique (FNRS), Consejo Superior de Investigaciones Científicas, German Research Foundation (LU 1944/3-1), SciLifeLab/KAW national COVID-19 research program project (KAW 2020.0182), Swedish Research Council (2014-02569 and 2014-07606), Jeansson Stiftelser, Magnus Bergvalls Stiftelse, Technical University of Munich, Munich, Germany, Genotyping Laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Helsinki, Finland
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

  • Serrano Maciá, Marina
  • Simón, Jorge
  • González Rellán, María Jesús
  • Azkargorta, Mikel
  • Goikoetxea-Usandizaga, Naroa
  • Lopitz Otsoa, Fernando
  • Sáenz de Urturi, Diego
  • Rodríguez Agudo, Rubén
  • Lachiondo-Ortega, Sofia
  • Mercado Gómez, María
  • Gutiérrez de Juan, Virginia
  • Bizkarguenaga-Uribiarte, Maider
  • Fernández-Ramos, David
  • Buqué, Xabier
  • Baselli, Guido Alessandro
  • Valenti, Luca
  • Iruzubieta, Paula
  • Crespo, Javier
  • Villa, Erica
  • Banales, Jesus
  • Avila, Matias A.
  • Marin, Jose
  • Aspichueta, Patricia
  • Sutherland, James D.
  • Barrio, Rosa
  • Mayor, Ugo
  • Elortza, Felix
  • Xirodimas, Dimitris
  • Nogueiras Pozo, Rubén
  • Delgado, Teresa
  • Martínez Chantar, María Luz
Objective: Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods: Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hepatocytes and pre-clinical mouse models of diet-induced NAFLD, male adult C57BL/6 mice, and the AlfpCre transgenic mice infected with AAV-DIO-shNedd8. Results: Neddylation inhibition reduced lipid accumulation in oleic acid-stimulated mouse primary hepatocytes and ameliorated liver steatosis, preventing lipid peroxidation and inflammation in the mouse models of diet-induced NAFLD. Under these conditions, increased Deptor levels and the concomitant repression of mTOR signaling were associated with augmented fatty acid oxidation and reduced lipid content. Moreover, Deptor silencing in isolated mouse hepatocytes abolished the anti-steatotic effects mediated by neddylation inhibition. Finally, serum NEDD8 levels correlated with hepatic neddylation during the disease progression in the clinical and pre-clinical models. Conclusions: Overall, the upregulation of Deptor, driven by neddylation inhibition, is proposed as a novel effective target and therapeutic approach to tackle NAFLD
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  • Martínez Arranz, Ibon
  • Bruzzone, Chiara
  • Noureddin, Mazen
  • Gil Redondo, Rubén
  • Mincholé, Itziar
  • Bizkarguenaga, Maider
  • Arretxe Oliden, Enara
  • Iruarrizaga Lejarreta, Marta
  • Fernández Ramos, David
  • Lopitz Otsoa, Fernando
  • Mayo, Rebeca
  • Embade, Nieves
  • Newberry, Elizabeth
  • Mittendorf, Bettina
  • Izquierdo Sánchez, Laura
  • Smid, Vaclav
  • Arnold, Jorge
  • Iruzubieta, Paula
  • Pérez Castaño, Ylenia
  • Krawczyk, Marcin
  • Martínez de Marigorta Izaga, Edorta
  • Morrison, Martine C.
  • Kleemann, Robert
  • Martín Duce, Antonio
  • Hayardeny, Liat
  • Vitek, Libor
  • Bruha, Radan
  • Aller de la Fuente, Rocio
  • Crespo, Javier
  • Romero Gómez, Manuel
  • Bañales Asurmendi, Jesús María
  • Arrese, Marco
  • Cusi, Kenneth
  • Bugianesi, Elisabetta
  • Klein, Samuel
  • Lu, Shelly C.
  • Anstee, Quentin M.
  • Millet Aguilar-Galindo, Oscar
  • Davidson, Nicholas O.
  • Alonso, Cristina
  • Mato, José M.
Background and Aims We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and Results We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6, and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (R01DK123763, R01DK119437, HL151328, P30DK52574, P30DK56341, and UL1TR002345); Ministerio de Economía y Competitividad de España (SAF2017-88041-R); Ministerio de Economía y Competitividad de España for the Severo Ochoa Excellence Accreditation (SEV-2016-0644); CIBERehd (Biomedical Research Center in Hepatic and Digestive Diseases) and Netherlands Organization for Applied Scientific Research Program (PMC13 and PMC15); Spanish Carlos III Health Institute (PI15/01132 and PI18/01075); Miguel Servet Program (CON14/00129 and CPII19/00008); Fondo Europeo de Desarrollo Regional, CIBERehd, Department of Industry of the Basque Country (Elkartek: KK-2020/00008); La Caixa Scientific Foundation (HR17-00601); Liver Investigation: Testing Marker Utility in Steatohepatitis consortium funded by the Innovative Medicines Initiative Program of the European Union (777377), which receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA; Newcastle NIHR Biomedical Research Center; Czech Ministry of Health (RVO-VFN64165/2020); Fondo Nacional De Ciencia y Tecnología de Chile (1191145); and the Comisión Nacional de Investigación, Ciencia y Tecnología (AFB170005, CARE Chile UC); Agencia Nacional de Investigación y Desarrollo (ANID ACE 210009); European Union's Horizon 2020 Research and Innovation Program (825510).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations.

  • Goikoetxea Agirre, Ane Josune
  • COVICAT Study Group
  • Aachen Study (COVAS)
  • Norwegian SARS CoV-2 Study Group
  • Pa Study Group
  • STORM Study Group
  • The Humanitas Task Force
  • The Humanitas Gavazzeni Task Force
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung., S.E.H. and C.A.S. partially supported genotyping through a philanthropic donation. A.F. and D.E. were supported by a grant from the German Federal Ministry of Education and COVID-19 grant Research (BMBF; ID:01KI20197); A.F., D.E. and F.D. were supported by the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). D.E. was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). D.E., K.B. and S.B. acknowledge the Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). T.L.L., A.T. and O.Ö. were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 279645989; 433116033; 437857095. M.W. and H.E. are supported by the German Research Foundation (DFG) through the Research Training Group 1743, ‘Genes, Environment and Inflammation’. L.V. received funding from: Ricerca Finalizzata Ministero della Salute (RF-2016-02364358), Italian Ministry of Health ‘CV PREVITAL’—strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana; The European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- and for the project ‘REVEAL’; Fondazione IRCCS Ca’ Granda ‘Ricerca corrente’, Fondazione Sviluppo Ca’ Granda ‘Liver-BIBLE’ (PR-0391), Fondazione IRCCS Ca’ Granda ‘5permille’ ‘COVID-19 Biobank’ (RC100017A). A.B. was supported by a grant from Fondazione Cariplo to Fondazione Tettamanti: ‘Bio-banking of Covid-19 patient samples to support national and international research (Covid-Bank). This research was partly funded by an MIUR grant to the Department of Medical Sciences, under the program ‘Dipartimenti di Eccellenza 2018–2022’. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP (The Institute for Health Science Research Germans Trias i Pujol) IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). M.M. received research funding from grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National RDI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (European Regional Development Fund (FEDER)-Una manera de hacer Europa’). B.C. is supported by national grants PI18/01512. X.F. is supported by the VEIS project (001-P-001647) (co-funded by the European Regional Development Fund (ERDF), ‘A way to build Europe’). Additional data included in this study were obtained in part by the COVICAT Study Group (Cohort Covid de Catalunya) supported by IsGlobal and IGTP, European Institute of Innovation & Technology (EIT), a body of the European Union, COVID-19 Rapid Response activity 73A and SR20-01024 La Caixa Foundation. A.J. and S.M. were supported by the Spanish Ministry of Economy and Competitiveness (grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36). A.J. was also supported by national grant PI17/00019 from the Acción Estratégica en Salud (ISCIII) and the European Regional Development Fund (FEDER). The Basque Biobank, a hospital-related platform that also involves all Osakidetza health centres, the Basque government’s Department of Health and Onkologikoa, is operated by the Basque Foundation for Health Innovation and Research-BIOEF. M.C. received Grants BFU2016-77244-R and PID2019-107836RB-I00 funded by the Agencia Estatal de Investigación (AEI, Spain) and the European Regional Development Fund (FEDER, EU). M.R.G., J.A.H., R.G.D. and D.M.M. are supported by the ‘Spanish Ministry of Economy, Innovation and Competition, the Instituto de Salud Carlos III’ (PI19/01404, PI16/01842, PI19/00589, PI17/00535 and GLD19/00100) and by the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018, COVID-Premed, COVID GWAs). The position held by Itziar de Rojas Salarich is funded by grant FI20/00215, PFIS Contratos Predoctorales de Formación en Investigación en Salud. Enrique Calderón’s team is supported by CIBER of Epidemiology and Public Health (CIBERESP), ‘Instituto de Salud Carlos III’. J.C.H. reports grants from Research Council of Norway grant no 312780 during the conduct of the study. E.S. reports grants from Research Council of Norway grant no. 312769. The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). P.K. Bergisch Gladbach, Germany and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. He is supported by the German Federal Ministry of Education and Research (BMBF). O.A.C. is supported by the German Federal Ministry of Research and Education and is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—CECAD, EXC 2030–390661388. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, BMBF and The States of Saarland and Lower Saxony. K.U.L. is supported by the German Research Foundation (DFG, LU-1944/3-1). Genotyping for the BoSCO study is funded by the Institute of Human Genetics, University Hospital Bonn. F.H. was supported by the Bavarian State Ministry for Science and Arts. Part of the genotyping was supported by a grant to A.R. from the German Federal Ministry of Education and Research (BMBF, grant: 01ED1619A, European Alzheimer DNA BioBank, EADB) within the context of the EU Joint Programme—Neurodegenerative Disease Research (JPND). Additional funding was derived from the German Research Foundation (DFG) grant: RA 1971/6-1 to A.R. P.R. is supported by the DFG (CCGA Sequencing Centre and DFG ExC2167 PMI and by SH state funds for COVID19 research). F.T. is supported by the Clinician Scientist Program of the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). C.L. and J.H. are supported by the German Center for Infection Research (DZIF). T.B., M.M.B., O.W. und A.H. are supported by the Stiftung Universitätsmedizin Essen. M.A.-H. was supported by Juan de la Cierva Incorporacion program, grant IJC2018-035131-I funded by MCIN/AEI/10.13039/501100011033. E.C.S. is supported by the Deutsche Forschungsgemeinschaft (DFG; SCHU 2419/2-1).
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

rs641738C>T nearMBOAT7is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

  • Teo, Kevin
  • Abeysekera, Kushala W.M.
  • Adams, Leon
  • Aigner, Elmar
  • Anstee, Quentin M.
  • Bañales Asurmendi, Jesús María
  • Banerjee, Rajarshi
  • Basu, Priyadarshi
  • Berg, Thomas
  • Bhatnagar, Pallav
  • Buch, Stephan
  • Canbay, Ali
  • Caprio, Sonia
  • Chatterjee, Ankita
  • Chen, Yii-Der Ida
  • Chowdhury, Abhijit
  • Daly, Ann K.
  • Datz, Christian
  • De Gracia Hahn, Dana
  • DiStefano, Johanna K.
  • Dong, Jiawen
  • Duret, Amedine
  • EU-PNAFLD Investigators
  • Emdin, Connor
  • Fairey, Madison
  • Gerhard, Glenn S.
  • GOLD Consortium
  • Guo, Xiuqing
  • Hampe, Jochen
  • Hickman, Matthew
  • Heintz, Lena
  • Hudert, Christian
  • Hunter, Harriet
  • Kelly, Matt
  • Kozlitina, Julia
  • Krawczyk, Marcin
  • Lammert, Frank
  • Langenberg, Claudia
  • Lavine, Joel
  • Li, Lin
  • Lim, Hong Kai
  • Loomba, Rohit
  • Luukkonen, Panu K.
  • Melton, Phillip E.
  • Mori, Trevor A.
  • Palmer, Nicholette D.
  • Parisinos, Constantinos A.
  • Pillai, Sreekumar G.
  • Qayyum, Faiza
  • Reichert, Matthias C.
  • Romeo, Stefano
  • Rotter, Jerome I.
  • Im, Yu Ri
  • Santoro, Nicola
  • Schafmayer, Clemens
  • Speliotes, Elizabeth K.
  • Stender, Stefan
  • Stickel, Felix
  • Still, Christopher D.
  • Strnad, Pavel
  • Taylor, Kent D.
  • Tybjærg-Hansen, Anne
  • Umano, Giuseppina Rosaria
  • Utukuri, Mrudula
  • Valenti, Luca
  • Wagenknecht, Lynne E.
  • Wareham, Nicholas J.
  • Watanabe, Richard M.
  • Wattacheril, Julia
  • Yaghootkar, Hanieh
  • Yki-Järvinen, Hannele
  • Young, Kendra A.
  • Mann, Jake P.
Background & Aims: A common genetic variant near MBOAT7 (rs641738C>T) has been previously associated with hepatic fat and advanced histology in NAFLD; however, these findings have not been consistently replicated in the literature. We aimed to establish whether rs641738C>T is a risk factor across the spectrum of NAFLD and to characterise its role in the regulation of related metabolic phenotypes through a meta-analysis. Methods: We performed a meta-analysis of studies with data on the association between rs641738C>T genotype and liver fat, NAFLD histology, and serum alanine aminotransferase (ALT), lipids or insulin. These included directly genotyped studies and population-level data from genome-wide association studies (GWAS). We performed a random effects meta-analysis using recessive, additive and dominant genetic models. Results: Data from 1,066,175 participants (9,688 with liver biopsies) across 42 studies were included in the meta-analysis. rs641738C>T was associated with higher liver fat on CT/MRI (+0.03 standard deviations [95% CI 0.02-0.05], p(z) = 4.8x10(-5)) and diagnosis of NAFLD (odds ratio [OR] 1.17 [95% CI 1.05-1.3], p(z) = 0.003) in Caucasian adults. The variant was also positively associated with presence of advanced fibrosis (OR 1.22 [95% CI 1.03-1.45], p(z) = 0.021) in Caucasian adults using a recessive model of inheritance (CC + CT vs. TT). Meta-analysis of data from previous GWAS found the variant to be associated with higher ALT (p(z) = 0.002) and lower serum triglycerides (p(z) = 1.5x10(-4)). rs641738C>T was not associated with fasting insulin and no effect was observed in children with NAFLD. Conclusions: Our study validates rs641738C>T near MBOAT7 as a risk factor for the presence and severity of NAFLD in individuals of European descent. Lay summary: Fatty liver disease is a common condition where fat builds up in the liver, which can cause liver inflammation and scarring (including 'cirrhosis'). It is closely linked to obesity and diabetes, but some genes are also thought to be important. We did this study to see whether one specific change ('variant') in one gene ('MBOAT7') was linked to fatty liver disease. We took data from over 40 published studies and found that this variant near MBOAT7 is linked to more severe fatty liver disease. This means that drugs designed to work on MBOAT7 could be useful for treating fatty liver disease., J.P.M. is supported by a Wellcome Trust Fellowship (216329/Z/19/Z), a European Paediatric Research Society award and a Children's Liver Disease Foundation grant. The EU-PNAFLD is supported by an EASL Registry Grant. NIH grants: R01HD028016 (S.C.), R01DK111038 (S.C)., R01DK114504 (N.S.), DK091601 (J.K.D.) and UL1TR001105 (J.K.). Supported by the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (U01DK061718, U01DK061728, U01DK061731, U01DK061732, U01DK061734, U01DK061737, U01DK061738, U01DK061730, and U01DK061713); the National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058, and UL1TR001881); and the NIDDK (DK063491 to the Southern California Diabetes Endocrinology Research Center). This study was supported by the German Federal Ministry for Education and Research (BmBF) through the Livers Systems Medicine (LiSyM) project. This work was supported by grants from the Swiss National Funds (SNF no. 310030_169196) and the Swiss Foundation for Alcohol Research (SSA) to F.S. This Raine Study was supported by the National Health and Medical Research Council of Australia (grant numbers 403981, 353514 and 572613). The UK Medical Research Council and Wellcome (grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. ALSPAC GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. A comprehensive list of grants funding is available on the ALSPAC website (www.bristol.ac.uk/alspac/external/documents/grant-acknowledgemen ts.pdf); this research was specifically funded by grants from MRC and Alcohol Research UK (MR/L022206/1) and NIH (5R01AA018333-05) to K.W.M.A. and M.H. L.V. was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. German Federal Ministry of Education and Research (BMBF LiSyM 031L0051 to F.L.). P.L. is supported by grants from the Sigrid Juselius Foundation and the Novo Nordisk Foundation. The Fenland study was funded by grants to the MRC Epidemiology Unit (MC UU12015/1, MC UU 12015/5). R.B. and M.K. are employees of and shareholders in Perspectum Diagnostics Ltd. C.A.P. is funded by aWellcome Trust Clinical PhD Programme (206274/Z/17/Z). J.M.B. is supported by the Spanish Carlos III Health Institute (ISCIII; PI15/01132, PI18/01075, CIBERehd, and Miguel Servet Program CON14/00129) cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) and La Caixa Scientific Foundation (HR17-00601). Research from the GUARDIAN Study was supported DK085175 and DK118062, and phenotyping in IRASFS was supported by HL060944, HL061019, HL060919 and HL060894 IRASFS from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). H.Y. is funded by a Diabetes UK RD Lawrence fellowship (17/0005594). Q.M.A. and A.D. supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. Q.M.A., A.D., L.V. and A.G. are members of the LITMUS (Liver Investigation: Testing Biomarker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377. Q.M.A.
Addi. Archivo Digital para la Docencia y la Investigación
Publication Artículo científico (JournalArticle)

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via DEPTOR-mTOR axis

  • Serrano Maciá, Marina
  • Simon, Jorge
  • González Rellán, María Jesús
  • Azkargorta, Mikel
  • Goikoetxea Usandizaga, Naroa
  • Lopitz Otsoa, Fernando
  • Saenz de Urturi Indart, Diego
  • Rodríguez Agudo, Rubén
  • Lachiondo Ortega, Sofía
  • Mercado Gómez, María
  • Gutiérrez de Juan, Virginia
  • Bizkarguenaga, Maider
  • Fernández Ramos, David
  • Buqué García, Xabier
  • Baselli, Guido A.
  • Valenti, Luca
  • Iruzubieta, Paula
  • Crespo, Javier
  • Villa, Erica
  • Bañales Asurmendi, Jesús María
  • Ávila, Matías A.
  • Marín, José J. G.
  • Aspichueta Celaá, Patricia
  • Sutherland, James D.
  • Barrio Olano, María Rosa
  • Mayor Martínez, Ugo
  • Elortza, Felix
  • Xirodimas, Dimitri
  • Nogueiras Pozo, Rubén
  • Delgado, Teresa C.
  • Martínez Chantar, María Luz
[EN] Objective: Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods: Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hepatocytes and pre-clinical mouse models of diet-induced NAFLD, male adult C57BL/6 mice, and the AlfpCre transgenic mice infected with AAV-DIO-shNedd8. Results: Neddylation inhibition reduced lipid accumulation in oleic acid-stimulated mouse primary hepatocytes and ameliorated liver steatosis, preventing lipid peroxidation and inflammation in the mouse models of diet-induced NAFLD. Under these conditions, increased Deptor levels and the concomitant repression of mTOR signaling were associated with augmented fatty acid oxidation and reduced lipid content. Moreover, Deptor silencing in isolated mouse hepatocytes abolished the anti-steatotic effects mediated by neddylation inhibition. Finally, serum NEDD8 levels correlated with hepatic neddylation during the disease progression in the clinical and pre-clinical models, This work was supported by grants from Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), ELKARTEK 2016, Departamento de Industria del Gobierno Vasco (to M.L.M C), Ministerio de Ciencia, Innovación y Universidades MICINN: SAF2017-87301-R, and RTI2018-096759-A-100 integrado en el Plan Estatal de Investigación Científica y Técnica y Innovación, cofinanciado con Fondos FEDER (to M.L.M T.C.D respectively); MCIU/AEI/FEDER, UE (RTI2018-095134-B- 100) (to P.A.), AECC Bizkaia (M.S-M); Asociación Española contra el Cáncer (T.C.D), Fundación Científica de la Asociación Española Contra el Cáncer (AECC Scientific Foundation) Rare Tumor Calls 2017 (to M.L.M, J.M.B., M.A.A., J.J.G.M.), La Caixa Foundation Program (to M.L.M and J.M.B.), 2018 BBVA Foundation Grants for Scientific Research Teams (to M.L.M.-C.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971-16 (P.A.). MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (to LV), the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- “Liver Investigation: Testing Marker Utility in Steatohepatitis” (to LV), Fondazione IRCCS Ca’ Granda “Liver BIBLE” PR-0391, Fondazione IRCCS Ca’ Granda core COVID-19 Biobank (RC100017A) (to LV). This research was funded by the CIBERehd (EHD15PI05/2016) and “Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III”, Spain (PI16/00598 and PI19/ 00819, co-funded by European Regional Development Fund/European Social Fund, “Investing in your future”); Spanish Ministry of Economy, Industry and Competitiveness (SAF2016-75197-R); “Junta de Castilla y Leon” (SA063P17); AECC Scientific Foundation (2017/2020), Spain; “Centro Internacional sobre el Envejecimiento” (OLD-HEPAMARKER, 0348_CIE_6_E), Spain; University of Salamanca Foundation, Spain (PC-TCUE18-20_051), and Fundació Marato TV3 (Ref. 201916e31), Spain. RB acknowledges BFU2017-84653-P (MINECO/FEDER, EU), SEV-2016-0644 (Severo Ochoa Excellence Program), 765445-EU (UbiCODE Program), SAF2017-90900-REDT (UBIRed Program), and IT1165-19 (Basque Country Government). Ciberehd_ISCIII_MINECO is funded by the Instituto de Salud Carlos III. We thank MINECO for the Severo Ochoa Excellence Accreditation to CIC bioGUNE (SEV-2016-0644). Finally, we would like to acknowledge Begoña Rodríguez Iruretagoyena for the technical support provided.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

  • Nakanishi, Tomoko
  • Pigazzini, Sara
  • Degenhardt, Frauke
  • Cordioli, Mattia
  • Butler-Laporte, Guillaume
  • Maya-Miles, Douglas
  • Nafría-Jiménez, Beatriz
  • Bouysran, Youssef
  • Niemi, Mari
  • Palom, Adriana
  • Ellinghaus, David
  • Khan, Atlas
  • Martínez-Bueno, Manuel
  • Rolker, Selina
  • Amitano, Sara
  • Roade, Luisa
  • FinnGen
  • The COVID-19 Host Genetics Initiative
  • Fava, Francesca
  • Spinner, Christoph D.
  • Prati, Daniele
  • Bernardo, David
  • García, Federico
  • Darcis, Gilles
  • Fernández-Cadenas, Israel
  • Holter, Jan Cato
  • Banales, Jesús M.
  • Frithiof, Robert
  • Kiryluk, Krzysztof
  • Duga, Stefano
  • Asselta, Rosanna
  • Costa Pereira, Alexandre de
  • Romero-Gómez, Manuel
  • Bujanda, Luis
  • Hov, Johannes R.
  • Migeotte, Isabelle
  • Renieri, Alessandra
  • Planas, Anna M.
  • Ludwig, Kerstin
  • Buti, María
  • Rahmouni, Souad
  • Alarcón-Riquelme, M. E.
  • Schulte, Eva C.
  • Franke, Andre
  • Karlsen, Tom H.
  • Valenti, Luca
  • Zeberg, Hugo
  • Richards, Brent
  • Ganna, Andrea
Background There is considerable variability in COVID-19 outcomes amongst younger adults—and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. Method The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. Findings We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2–1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3–1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. Interpretation The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality—and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management., AG has received support by NordForsk Nordic Trial Alliance (NTA) grant, by Academy of Finland Fellow grant N. 323116 and the Academy of Finland for PREDICT consortium N. 340541. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR) (365825 and 409511), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation (CFI), the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante (FRQS). TN is supported by a research fellowship of the Japan Society for the Promotion of Science for Young Scientists. GBL is supported by a CIHR scholarship and a joint FRQS and Quebec Ministry of Health and Social Services scholarship. JBR is supported by an FRQS Clinical Research Scholarship. Support from Calcul Quebec and Compute Canada is acknowledged. TwinsUK is funded by the Welcome Trust, the Medical Research Council, the European Union, the National Institute for Health Research-funded BioResource and the Clinical Research Facility and Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust in partnership with King's College London. The Biobanque Quebec COVID19 is funded by FRQS, Genome Quebec and the Public Health Agency of Canada, the McGill Interdisciplinary Initiative in Infection and Immunity and the Fonds de Recherche Quebec Sante. These funding agencies had no role in the design, implementation or interpretation of this study. The COVID19-Host(a)ge study received infrastructure support from the DFG Cluster of Excellence 2167 Precision Medicine in Chronic Inflammation (PMI) (DFG Grant: EXC2167). The COVID19-Host(a)ge study was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). Genotyping in COVID19-Host(a)ge was supported by a philantropic donation from Stein Erik Hagen. The COVID GWAs, Premed COVID-19 study (COVID19-Host(a)ge_3) was supported by Grupo de Trabajo en Medicina Personalizada contra el COVID-19 de Andalucia and also by the Instituto de Salud Carlos III (CIBERehd and CIBERER). Funding comes from COVID-19-GWAS, COVID-PREMED initiatives. Both of them are supported by Consejeria de Salud y Familias of the Andalusian Government. DMM is currently funded by the the Andalussian government (Proyectos Estrategicos-Fondos Feder PE-0451-2018). The Columbia University Biobank was supported by Columbia University and the National Center for Advancing Translational Sciences, NIH, through Grant Number UL1TR001873. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Columbia University. The SPGRX study was supported by the Consejeria de Economia, Conocimiento, Empresas y Universidad #CV20-10150. The GEN-COVID study was funded by: the MIUR grant Dipartimenti di Eccellenza 2018-2020 to the Department of Medical Biotechnologies University of Siena, Italy; the Intesa San Paolo 2020 charity fund dedicated to the project NB/2020/0119; and philanthropic donations to the Department of Medical Biotechnologies, University of Siena for the COVID-19 host genetics research project (D.L n.18 of March 17, 2020). Part of this research project is also funded by Tuscany Region Bando Ricerca COVID-19 Toscana grant to the Azienda Ospedaliero Universitaria Senese (CUP I49C20000280002). Authors are grateful to: the CINECA consortium for providing computational resources; the Network for Italian Genomes (NIG) (http://www.nig.cineca.it) for its support; the COVID-19 Host Genetics Initiative (https://www.covid19hg.org/); the Genetic Biobank of Siena, member of BBMRI-IT, Telethon Network of Genetic Biobanks (project no. GTB18001), EuroBioBank, and RD-Connect, for managing specimens. Genetics against coronavirus (GENIUS), Humanitas University (COVID19-Host(a)ge_4) was supported by Ricerca Corrente (Italian Ministry of Health), intramural funding (Fondazione Humanitas per la Ricerca). The generous contribution of Banca Intesa San Paolo and of the Dolce&Gabbana Fashion Firm is gratefully acknowledged. Data acquisition and sample processing was supported by COVID-19 Biobank, Fondazione IRCCS Ca Granda Milano; LV group was supported by MyFirst Grant AIRC n.16888, Ricerca Finalizzata Ministero della Salute RF-2016-02364358, Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, the European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- Liver Investigation: Testing Marker Utility in Steatohepatitis, Programme Photonics under grant agreement 101016726 for the project REVEAL: Neuronal microscopy for cell behavioural examination and manipulation, Fondazione Patrimonio Ca' Granda Liver Bible PR-0361. DP was supported by Ricerca corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, CV PREVITAL Strategie di prevenzione primaria nella popolazione Italiana Ministero della Salute, and Associazione Italiana per la Prevenzione dell'Epatite Virale (COPEV). Genetic modifiers for COVID-19 related illness (BeLCovid_1) was supported by the Fonds Erasme. The Host genetics and immune response in SARS-Cov-2 infection (BelCovid_2) study was supported by grants from Fondation Leon Fredericq and from Fonds de la Recherche Scientifique (FNRS). The INMUNGEN-CoV2 study was funded by the Consejo Superior de Investigaciones Cientificas. KUL is supported by the German Research Foundation (LU 1944/3-1) SweCovid is funded by the SciLifeLab/KAW national COVID-19 research program project grant to Michael Hultstrom (KAW 2020.0182) and the Swedish Research Council to Robert Frithiof (2014-02569 and 2014-07606). HZ is supported by Jeansson Stiftelser, Magnus Bergvalls Stiftelse. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. Genotyping for the COMRI cohort was performed and funded by the Genotyping Laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Helsinki, Finland., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease

  • Hardy, Timothy
  • Wonders, Kristy
  • Younes, Ramy
  • Aithal, Guruprasad P.
  • Aller, Rocío
  • Allison, Michael
  • Bedossa, Pierre
  • Betsou, Fay
  • Boursier, Jerome
  • Brosnan, M. Julia
  • Burt, Alastair
  • Cobbold, Jeremy
  • Cortez-Pinto, Helena
  • Day, Chris P.
  • Dufour, Jean-François
  • Ekstedt, Mattias
  • Francque, Sven
  • Harrison, Stephen A.
  • Miele, Luca
  • Nasr, Patrik
  • Papatheodoridis, George
  • Petta, Salvatore
  • Tiniakos, Dina
  • Torstenson, Richard
  • Valenti, Luca
  • Holleboom, Adriaan G.
  • Yki-Järvinen, Hannele
  • Geier, Andreas
  • Romero-Gómez, Manuel
  • Ratziu, Vlad
  • Bugianesi, Elisabetta
  • Schattenberg, Jörn M.
  • Anstee, Quentin M.
© 2020 The Author(s)., Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There is significant variability in the disease course: the majority exhibit only fat accumulation in the liver but a significant minority develop a necroinflammatory form of the disease (non-alcoholic steatohepatitis, NASH) that may progress to cirrhosis and hepatocellular carcinoma. At present our understanding of pathogenesis, disease natural history and long-term outcomes remain incomplete. There is a need for large, well characterised patient cohorts that may be used to address these knowledge gaps and to support the development of better biomarkers and novel therapies. The European NAFLD Registry is an international, prospectively recruited observational cohort study that aims to establish a large, highly-phenotyped patient cohort and linked bioresource. Here we describe the infrastructure, data management and monitoring plans, and the standard operating procedures implemented to ensure the timely and systematic collection of high-quality data and samples. Already recruiting subjects at secondary/tertiary care centres across Europe, the Registry is supporting the European Union IMI2-funded LITMUS ‘Liver Investigation: Testing Marker Utility in Steatohepatitis’ consortium, which is a major international effort to robustly validate biomarkers that diagnose, risk stratify and/or monitor NAFLD progression and liver fibrosis stage. The European NAFLD Registry has the demonstrable capacity to support research and biomarker development at scale and pace., The European NAFLD Registry is supported by the LITMUS (Liver Investigation: Testing Biomarker Utility in Steatohepatitis) consortium funded by the European Union Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377, which receives support from the Horizon 2020 Framework Program of European Union and EFPIA. It has also received support from the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, the FLIP consortium funded by the Framework Program 7 of the European Union under grant agreement 241762, and an EASL Registry Grant from the European Association for the Study of the Liver.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

  • Selvaraj, Emmanuel Anandraj
  • Mózes, Ferenc Emil
  • Jayaswal, Arjun Narayan Ajmer
  • Zafarmand, Mohammad Hadi
  • Vali, Yasaman
  • Lee, Jenny A.
  • Levick, Christina Kim
  • Young, Liam Arnold Joseph
  • Palaniyappan, Naaventhan
  • Liu, Chang-Hai
  • Aithal, Guruprasad P.
  • Romero-Gómez, Manuel
  • Brosnan, M. Julia
  • Tuthill, Theresa A.
  • Anstee, Quentin M.
  • Neubauer, Stefan
  • Harrison, Stephen A.
  • Bossuyt, Patrick M.
  • Pavlides, Michael
[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH)., [Methods] PubMED/MEDLINE, EMBASE and the Cochrane Library were searched for studies examining the diagnostic accuracy of these index tests, against histology as the reference standard, in adult patients with NAFLD. Two authors independently screened and assessed methodological quality of studies and extracted data. Summary estimates of sensitivity, specificity and area under the curve (sAUC) were calculated for fibrosis stages and NASH, using a random effects bivariate logit-normal model., [Results] We included 82 studies (14,609 patients). Meta-analysis for diagnosing fibrosis stages was possible in 53 VCTE, 11 MRE, 12 pSWE and 4 2DSWE studies, and for diagnosing NASH in 4 MRE studies. sAUC for diagnosis of significant fibrosis were: 0.83 for VCTE, 0.91 for MRE, 0.86 for pSWE and 0.75 for 2DSWE. sAUC for diagnosis of advanced fibrosis were: 0.85 for VCTE, 0.92 for MRE, 0.89 for pSWE and 0.72 for 2DSWE. sAUC for diagnosis of cirrhosis were: 0.89 for VCTE, 0.90 for MRE, 0.90 for pSWE and 0.88 for 2DSWE. MRE had sAUC of 0.83 for diagnosis of NASH. Three (4%) studies reported intention-to-diagnose analyses and 15 (18%) studies reported diagnostic accuracy against pre-specified cut-offs., [Conclusions] When elastography index tests are acquired successfully, they have acceptable diagnostic accuracy for advanced fibrosis and cirrhosis. The potential clinical impact of these index tests cannot be assessed fully as intention-to-diagnose analyses and validation of pre-specified thresholds are lacking., [Lay summary] Non-invasive tests that measure liver stiffness or use magnetic resonance imaging (MRI) have been suggested as alternatives to liver biopsy for assessing the severity of liver scarring (fibrosis) and fatty inflammation (steatohepatitis) in patients with non-alcoholic fatty liver disease (NAFLD). In this study, we summarise the results of previously published studies on how accurately these non-invasive tests can diagnose liver fibrosis and inflammation, using liver biopsy as the reference. We found that some techniques that measure liver stiffness had a good performance for the diagnosis of severe liver scarring., This work has been undertaken as part of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project. The LITMUS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and Europen Federation of Pharmaceutical Industries and Associations (efpia.eu)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease?

  • Lazarus, Jeffrey V.
  • Palayew, Adam
  • Carrieri, Patrizia
  • Ekstedt, Mattias
  • Marchesini, Giulio
  • Novak, Katja
  • Ratziu, Vlad
  • Romero-Gómez, Manuel
  • Tacke, Frank
  • Zelber-Sagi, Shira
  • Cortez-Pinto, Helena
  • Anstee, Quentin M.
[Background & Aims] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe., [Methods] In June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100., [Results] The analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management., [Conclusions] The NAFLD Preparedness Index indicates substantial variation between countries’ readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place., [Lay summary] Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied., The original data collection was funded by the EASL International Liver Foundation with support from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. The statistical analysis was funded by the EASL International Liver Foundation with support from Bristol-Myers-Squibb Company, Intercept, and Genfit. JVL is supported by a Spanish Ministry of Science, Innovation and Universities Miguel Servet grant (Instituto de Salud Carlos III/ESF, European Union [CP18/00074]) and further acknowledges institutional support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa 2019–2023’ Programme (CEX2018-000806-S), and support from the Government of Catalonia through the CERCA Programme. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, and MRG are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator. AP, PC, GM, KN, FT, and SZS have no financial support statements to disclose., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Otros (Other)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

  • Degenhardt, Frauke
  • Ellinghaus, David
  • Juzenas, Simonas
  • Lerga-Jaso, Jon
  • Wendorff, Mareike
  • Maya-Miles, Douglas
  • Uellendahl-Werth, Florian
  • ElAbd, Hesham
  • Rühlemann, Malte C.
  • Arora, Jatin
  • Özer, Onur
  • Morilla Romero de la Osa, R.
  • Paccapelo, Cinzia
  • Lehmann, Clara
  • Angelini, Claudio
  • Cappadona, Claudio
  • Garrido Chercoles, Adolfo
  • Azuure, Clinton
  • Riveiro-Barciela, Mar
  • COVICAT study group
  • Rosenstiel, Philip
  • Santoro, Luigi
  • Solligård, Erik
  • Covid-19 Aachen Study (COVAS)
  • Myhre, Ronny
  • Bianco, Cristiana
  • Badalamenti, Salvatore
  • Cea, Cristina
  • Müller, Fredrik
  • Sander, Leif Erik
  • Hemmrich-Stanisak, Georg
  • Bellani, Giacomo
  • Bacher, Petra
  • Toapanta, David
  • Grasselli, Giacomo
  • Pezzoli, Gianni
  • Costantino, Giorgio
  • Vadla, May Sissel
  • Albano, Giovanni
  • Niemi, Mari
  • Buti, María
  • Cardamone, Giulia
  • Valsecchi, Maria Grazia
  • Koehler, Philipp
  • Lippert, Lena J.
  • Salazar, Adolfo de
  • Bellelli, Giuseppe
  • Citerio, Giuseppe
  • Foti, Giuseppe
  • Lamorte, Giuseppe
  • Matullo, Giuseppe
  • Baselli, Guido
  • Kurihara, Hayato
  • Neb, Holger
  • Tran, Florian
  • Duga, Stefano
  • Klein, Sebastian
  • Contro, Ernesto
  • Wacker, Eike M.
  • Gutiérrez-Stampa, María A.
  • Ciesek, Sandra
  • My, Ilaria
  • Kurth, Ingo
  • Hernández, Isabel
  • Pink, Isabell
  • Zoller, Heinz
  • Rojas, Itziar de
  • Galván-Femenia, Iván
  • Holter, Jan Cato
  • Schommers, Philipp
  • Hernández-Tejero, María
  • Bujanda, Luis
  • Afset, Jan Egil
  • Heyckendorf, Jan
  • Kässens, Jan
  • May, Sandra
  • Binatti, Eleonora
  • Carrabba, Maria
  • Wienbrandt, Lars
  • Damås, Jan Kristian
  • Rybniker, Jan
  • Suwalski, Phillip
  • Altmüller, Janine
  • Vehreschild, Maria J. G. T.
  • Ampuero, Javier
  • Ceriotti, Ferruccio
  • Martín, Javier
  • Schulte, Eva C.
  • Erdmann, Jeanette
  • Banales, Jesús M.
  • Badia, Joan Ramon
  • Bombace, Sara
  • Dopazo, Joaquín
  • Pablo, Raúl de
  • Figuera Basso, Maria E.
  • Schneider, Jochen
  • Lihaug Hoff, Dag Arne
  • Blandino Ortiz, Aaron
  • García Sánchez, Félix
  • Bergan, Jonas
  • Hov, Johannes R.
  • Barretina, Jordi
  • Walter, Jörn
  • Hernández Quero, José
  • Goikoetxea-Aguirre, Josune
  • Navas, Enrique
  • Delgado, Juan
  • Marsal, Sara
  • Guerrero, Juan M.
  • Heidecker, Bettina
  • Roade, Luisa
  • Fazaal, Julia
  • Casalone, Elisabetta
  • Kraft, Julia
  • Lenz, Tobias L.
  • Schröder, Julia
  • Manunta, Maria
  • Ferrer, Ricard
  • Acosta-Herrera, Marialbert
  • D’Angiò, Mariella
  • Heggelund, Lars
  • Baldini, Marina
  • Cazzaniga, Marina
  • Grimsrud, Marit M.
  • Urrechaga, Eloisa
  • Cornberg, Markus
  • Pelusi, Serena
  • Galimberti, Daniela
  • García-Fernández, Alba-Estela
  • Volland, Sonja
  • Bals, Robert
  • Calderón, Enrique J.
  • Nöthen, Markus M.
  • Marquié, Marta
  • Castoldi, Massimo
  • Cordioli, Mattia
  • Cecconi, Maurizio
  • D’Amato, Mauro
  • Augustin, Max
  • Tomasi, Melissa
  • Prati, Daniele
  • Franke, Andre
  • Palom, Adriana
  • Paraboschi, Elvezia Maria
  • Bandera, Alessandra
  • Braun, Alice
  • Boada, Mercè
  • Dreher, Michael
  • Blanco-Grau, Albert
  • Seilmaier, Michael J.
  • Joannidis, Michael
  • Wittig, Michael
  • Mazzocco, Michela
  • Ludwig, Kerstin U.
  • Brunak, Søren
  • Haschka, David
  • Ciccarelli, Michele
  • Rodríguez-Gandía, Miguel
  • Bocciolone, Monica
  • Cid, Rafael de
  • Wilfling, Sibylle
  • Pontali, Emanuele
  • Miozzo, Monica
  • Imaz Ayo, Natale
  • Ramírez, Alfredo
  • Blay, Natalia
  • Raychaudhuri, Soumya
  • Mantovani, Alberto
  • Berger, Marc M.
  • Chueca, Natalia
  • Montano, Nicola
  • Braun, Nicole
  • Ludwig, Nicole
  • Valenti, Luca
  • Marx, Nikolaus
  • Fernández, Javier
  • Bosari, Silvano
  • Martínez, Nilda
  • Risnes, Kari
  • Reverter, Enric
  • Norwegian SARS-CoV-2 Study group
  • Jiménez, David
  • Cornely, Oliver A.
  • Witzke, Oliver
  • Palmieri, Orazio
  • Zanella, Alberto
  • Téllez, Luis
  • Pa COVID-19 Study Group
  • Karlsen, Tom H.
  • Faverio, Paola
  • Haider, Sammra
  • Preatoni, Paoletta
  • Terranova, Leonardo
  • Bonfanti, Paolo
  • Pestaña, David
  • Omodei, Paolo
  • Schreiber, Stefan
  • Romero-Gómez, Manuel
  • Heilmann-Heimbach, Stefanie
  • Aliberti, Stefano
  • Ripke, Stephan
  • Dudman, Susanne
  • Cherubini, Alessandro
  • Nkambule, Lindokuhle
  • Wesse, Tanja
  • Nebel, Almut
  • Banasik, Karina
  • Lenning, Ole Bernt
  • Teles, Ana
  • Albillos, Agustín
  • Zheng, Tenghao
  • The Humanitas COVID-19 Task Force
  • The Humanitas Gavazzeni COVID-19 Task Force
  • Bahmer, Thomas
  • Eggermann, Thomas
  • Illig, Thomas
  • Brenner, Thorsten
  • Pumarola, Tomàs
  • Müller, Karl Erik
  • Scarpini, Elio
  • Knopp, Lisa
  • Martinelli-Boneschi, Filippo
  • Medrano, Francisco Javier
  • Feldt, Torsten
  • Protti, Alessandro
  • Arana-Arri, Eunate
  • Folseraas, Trine
  • Gonzalez Cejudo, Trinidad
  • Landmesser, Ulf
  • Protzer, Ulrike
  • Kildal, Anders Benjamin
  • Gaede, Karoline I.
  • Hehr, Ute
  • Rimoldi, Valeria
  • Monzani, Valter
  • Muñiz-Diaz, Eduardo
  • Barreira, Ana
  • Gustad, Lise Tuset
  • Skogen, Vegard
  • Keitel, Verena
  • Kopfnagel, Verena
  • Biondi, Andrea
  • Aziz, Fátima
  • Pigazzini, Sara
  • Aghemo, Alessio
  • Friaza Patiño, Vicente
  • Andrade, Victor
  • Moreno, Victor
  • Azzolini, Elena
  • Albrecht, Wolfgang
  • Lleo, Ana
  • Peter, Wolfgang
  • Tentorio, Paolo
  • Garbarino, Lucia
  • Poller, Wolfgang
  • García-Etxebarria, Koldo
  • Farré, Xavier
  • Yi, Xiaoli
  • Wang, Xiaomin
  • García, Federico
  • Khodamoradi, Yascha
  • Sandoval, Elena
  • Gerussi, Alessio
  • Asselta, Rosanna
  • Karadeniz, Zehra
  • Gualtierotti, Roberta
  • Latiano, Anna
  • Tonby, Kristian
  • Goerg, Siegfried
  • Caballero-Garralda, Andrea
  • Ganna, Andrea
  • Gori, Andrea
  • Glück, Andreas
  • Lind, Andreas
  • Peyvandi, Flora
  • Gallego-Durán, Rocío
  • Tanck, Anja
  • Mesonero, Francisco
  • Castro Blázquez, Pedro
  • Helbig, Elisa T.
  • Sancho, Cristina
  • Hinney, Anke
  • Carreras Nolla, Anna
  • Fracanzani, Anna Ludovica
  • Peschuck, Anna
  • Cavallero, Annalisa
  • Dyrhol-Riise, Anne Ma
  • Ruello, Antonella
  • Julià, Antonio
  • Rodrigues, Pedro M.
  • Nieto Liñán, Rosa María
  • Schaefer, Marco
  • Ruiz, Agustín
  • Muscatello, Antonio
  • Kurth, Florian
  • Ostadreza, Mahnoosh
  • Pesenti, Antonio
  • Voza, Antonio
  • Rando-Segura, Ariadna
  • Solier-López, Aurora
  • España, Pedro Pablo
  • Schmidt, Axel
  • Cortes, Beatriz
  • Mateos, Beatriz
  • Izquierdo-Sanchez, Laura
  • Rodríguez-Frías, Francisco
  • Carpani, Rossana
  • Nafría-Jiménez, Beatriz
  • Schaefer, Benedikt
  • Jensen, Björn
  • Intxausti, Maider
  • Cáceres, Mario
  • Blasi, Francesco
  • Bellinghausen, Carla
  • Maj, Carlo
  • Ferrando, Carlos
  • Rachele Bettini, Laura
  • Horra, Carmen de la
  • Hanses, Frank
  • Quereda, Carmen
  • Mayer, Alena
  • Skurk, Carsten
  • Hoffmann, Per
  • Thibeault, Charlotte
  • Scollo, Chiara
  • Herr, Christian
  • Kogevinas, Manolis
  • Spinner, Christoph D.
  • Sumoy, Lauro
  • Malvestiti, Francesco
  • Gassner, Christoph
  • Invernizzi, Pietro
  • Lange, Christoph
  • Holten, Aleksander Rygh
  • Hu, Cinzia
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended GWAS meta-analysis of a well-characterized cohort of 3,260 COVID-19 patients with respiratory failure and 12,483 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen (HLA) region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a highly pleiotropic ∼0.9-Mb inversion polymorphism and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung., Andre Franke and David Ellinghaus were supported by a grant from the German Federal Ministry of Education and Research (01KI20197), Andre Franke, David Ellinghaus and Frauke Degenhardt were supported by the Deutsche Forschungsgemeinschaft Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC2167). David Ellinghaus was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). David Ellinghaus, Karina Banasik and Søren Brunak acknowledge the Novo Nordisk Foundation (grant NNF14CC0001 and NNF17OC0027594). Tobias L. Lenz, Ana Teles and Onur Özer were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 279645989; 433116033; 437857095. Mareike Wendorff and Hesham ElAbd are supported by the German Research Foundation (DFG) through the Research Training Group 1743, "Genes, Environment and Inflammation". This project was supported by a Covid-19 grant from the German Federal Ministry of Education and Research (BMBF; ID: 01KI20197). Luca Valenti received funding from: Ricerca Finalizzata Ministero della Salute RF2016-02364358, Italian Ministry of Health ""CV PREVITAL – strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana; The European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- and for the project ""REVEAL""; Fondazione IRCCS Ca' Granda ""Ricerca corrente"", Fondazione Sviluppo Ca' Granda ""Liver-BIBLE"" (PR-0391), Fondazione IRCCS Ca' Granda ""5permille"" ""COVID-19 Biobank"" (RC100017A). Andrea Biondi was supported by the grant from Fondazione Cariplo to Fondazione Tettamanti: "Biobanking of Covid-19 patient samples to support national and international research (Covid-Bank). This research was partly funded by a MIUR grant to the Department of Medical Sciences, under the program "Dipartimenti di Eccellenza 2018–2022". This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP. IGTP is part of the CERCA Program / Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIIIMINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). Marta Marquié received research funding from ant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National RDI Plan and financed by ISCIIISubdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa")., Beatriz Cortes is supported by national grants PI18/01512. Xavier Farre is supported by VEIS project (001-P-001647) (cofunded by European Regional Development Fund (ERDF), “A way to build Europe”). Additional data included in this study was obtained in part by the COVICAT Study Group (Cohort Covid de Catalunya) supported by IsGlobal and IGTP, EIT COVID-19 Rapid Response activity 73A and SR20-01024 La Caixa Foundation. Antonio Julià and Sara Marsal were supported by the Spanish Ministry of Economy and Competitiveness (grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36). Antonio Julià was also supported the by national grant PI17/00019 from the Acción Estratégica en Salud (ISCIII) and the FEDER. The Basque Biobank is a hospitalrelated platform that also involves all Osakidetza health centres, the Basque government's Department of Health and Onkologikoa, is operated by the Basque Foundation for Health Innovation and Research-BIOEF. Mario Cáceres received Grants BFU2016-77244-R and PID2019-107836RB-I00 funded by the Agencia Estatal de Investigación (AEI, Spain) and the European Regional Development Fund (FEDER, EU). Manuel Romero Gómez, Javier Ampuero Herrojo, Rocío Gallego Durán and Douglas Maya Miles are supported by the “Spanish Ministry of Economy, Innovation and Competition, the Instituto de Salud Carlos III” (PI19/01404, PI16/01842, PI19/00589, PI17/00535 and GLD19/00100), and by the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018, COVID-Premed, COVID GWAs). The position held by Itziar de Rojas Salarich is funded by grant FI20/00215, PFIS Contratos Predoctorales de Formación en Investigación en Salud. Enrique Calderón's team is supported by CIBER of Epidemiology and Public Health (CIBERESP), "Instituto de Salud Carlos III". Jan Cato Holter reports grants from Research Council of Norway grant no 312780 during the conduct of the study. Dr. Solligård: reports grants from Research Council of Norway grant no 312769. The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). Philipp Koehler has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. He is supported by the German Federal Ministry of Education and Research (BMBF)., Oliver A. Cornely is supported by the German Federal Ministry of Research and Education and is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – CECAD, EXC 2030 – 390661388. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. Genotyping was performed by the Genotyping laboratory of Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki. This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, BMBF and The States of Saarland and Lower Saxony. Kerstin U. Ludwig is supported by the German Research Foundation (DFG, LU-1944/3-1). Genotyping for the BoSCO study is funded by the Institute of Human Genetics, University Hospital Bonn. Frank Hanses was supported by the Bavarian State Ministry for Science and Arts. Part of the genotyping was supported by a grant to Alfredo Ramirez from the German Federal Ministry of Education and Research (BMBF, grant: 01ED1619A, European Alzheimer DNA BioBank, EADB) within the context of the EU Joint Programme – Neurodegenerative Disease Research (JPND). Additional funding was derived from the German Research Foundation (DFG) grant: RA 1971/6-1 to Alfredo Ramirez. Philip Rosenstiel is supported by the DFG (CCGA Sequencing Centre and DFG ExC2167 PMI and by SH state funds for COVID19 research). Florian Tran is supported by the Clinician Scientist Program of the Deutsche Forschungsgemeinschaft Cluster of Excellence “Precision Medicine in Chronic Inflammation” (EXC2167). Christoph Lange and Jan Heyckendorf are supported by the German Center for Infection Research (DZIF). Thorsen Brenner, Marc M Berger, Oliver Witzke und Anke Hinney are supported by the Stiftung Universitätsmedizin Essen. Marialbert Acosta-Herrera was supported by Juan de la Cierva Incorporacion program, grant IJC2018-035131-I funded by MCIN/AEI/10.13039/501100011033. Eva C Schulte is supported by the Deutsche Forschungsgemeinschaft (DFG; SCHU 2419/2-1)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Detailed stratified GWAS analysis for severe COVID-19 in four European populations

  • Degenhardt, Frauke
  • Ellinghaus, David
  • Juzenas, Simonas
  • Lerga-Jaso, Jon
  • Wendorff, Mareike
  • Maya-Miles, Douglas
  • Uellendahl-Werth, Florian
  • ElAbd, Hesham
  • Rühlemann, Malte C.
  • Arora, Jatin
  • Özer, Onur
  • Salazar, Adolfo de
  • Risnes, Kari
  • Banasik, Karina
  • Müller, Karl Erik
  • Gaede, Karoline I.
  • Pigazzini, Sara
  • García-Etxebarria, Koldo
  • Tonby, Kristian
  • Heggelund, Lars
  • Asselta, Rosanna
  • Sancho, Cristina
  • Ruiz, Agustín
  • Izquierdo-Sanchez, Laura
  • Rachele Bettini, Laura
  • Sumoy, Lauro
  • Garrido Chercoles, Adolfo
  • Sander, Leif Erik
  • Valsecchi, Maria Grazia
  • Klein, Sebastian
  • Hernández-Tejero, María
  • Vehreschild, Maria J. G. T.
  • Lihaug Hoff, Dag Arne
  • Roade, Luisa
  • Manunta, Maria
  • Acosta-Herrera, Marialbert
  • D’Angiò, Mariella
  • Baldini, Marina
  • Cazzaniga, Marina
  • Grimsrud, Marit M.
  • Urrechaga, Eloisa
  • Cornberg, Markus
  • Pelusi, Serena
  • Galimberti, Daniela
  • García-Fernández, Alba-Estela
  • Bals, Robert
  • Nöthen, Markus M.
  • Marquié, Marta
  • Castoldi, Massimo
  • Cordioli, Mattia
  • Cecconi, Maurizio
  • D’Amato, Mauro
  • Augustin, Max
  • Tomasi, Melissa
  • Prati, Daniele
  • Paraboschi, Elvezia Maria
  • Bandera, Alessandra
  • Braun, Alice
  • Boada, Mercè
  • Dreher, Michael
  • Blanco-Grau, Albert
  • Seilmaier, Michael J.
  • Joannidis, Michael
  • Wittig, Michael
  • Mazzocco, Michela
  • Haschka, David
  • Ciccarelli, Michele
  • Rodríguez-Gandía, Miguel
  • Bocciolone, Monica
  • Cid, Rafael de
  • Wilfling, Sibylle
  • Pontali, Emanuele
  • Miozzo, Monica
  • Imaz Ayo, Natale
  • Blay, Natalia
  • Mantovani, Alberto
  • Berger, Marc M.
  • Chueca, Natalia
  • Montano, Nicola
  • Braun, Nicole
  • Ludwig, Nicole
  • Valenti, Luca
  • Marx, Nikolaus
  • Bosari, Silvano
  • Martínez, Nilda
  • Reverter, Enric
  • Norwegian SARS-CoV-2 Study group
  • Jiménez, David
  • Cornely, Oliver A.
  • Witzke, Oliver
  • Palmieri, Orazio
  • Zanella, Alberto
  • Pa COVID-19 Study Group
  • Karlsen, Tom H.
  • Faverio, Paola
  • Preatoni, Paoletta
  • Terranova, Leonardo
  • Bonfanti, Paolo
  • Pestaña, David
  • Omodei, Paolo
  • Calderón, Enrique J.
  • Tentorio, Paolo
  • Castro Blázquez, Pedro
  • Rodrigues, Pedro M.
  • España, Pedro Pablo
  • Cáceres, Mario
  • Hoffmann, Per
  • Holten, Aleksander Rygh
  • Rosenstiel, Philip
  • Toapanta, David
  • Contro, Ernesto
  • Schommers, Philipp
  • Suwalski, Phillip
  • Pablo, Raúl de
  • Navas, Enrique
  • Ferrer, Ricard
  • Volland, Sonja
  • Franke, Andre
  • Brunak, Søren
  • Raychaudhuri, Soumya
  • Haider, Sammra
  • Schreiber, Stefan
  • Heilmann-Heimbach, Stefanie
  • Aliberti, Stefano
  • Ripke, Stephan
  • Dudman, Susanne
  • Cherubini, Alessandro
  • Nkambule, Lindokuhle
  • Wesse, Tanja
  • Nebel, Almut
  • Lenning, Ole Bernt
  • Albillos, Agustín
  • Zheng, Tenghao
  • The Humanitas COVID-19 Task Force
  • The Humanitas Gavazzeni COVID-19 Task Force
  • Bahmer, Thomas
  • Eggermann, Thomas
  • Illig, Thomas
  • Brenner, Thorsten
  • Pumarola, Tomàs
  • Knopp, Lisa
  • Martinelli-Boneschi, Filippo
  • Medrano, Francisco Javier
  • Feldt, Torsten
  • Protti, Alessandro
  • Arana-Arri, Eunate
  • Folseraas, Trine
  • Gonzalez Cejudo, Trinidad
  • Landmesser, Ulf
  • Protzer, Ulrike
  • Hehr, Ute
  • Rimoldi, Valeria
  • Monzani, Valter
  • Muñiz-Diaz, Eduardo
  • Barreira, Ana
  • Gustad, Lise Tuset
  • Skogen, Vegard
  • Keitel, Verena
  • Kopfnagel, Verena
  • Aziz, Fátima
  • Aghemo, Alessio
  • Friaza Patiño, Vicente
  • Andrade, Victor
  • Moreno, Victor
  • Azzolini, Elena
  • Albrecht, Wolfgang
  • Lleo, Ana
  • Peter, Wolfgang
  • Garbarino, Lucia
  • Poller, Wolfgang
  • Farré, Xavier
  • Yi, Xiaoli
  • Wang, Xiaomin
  • García, Federico
  • Khodamoradi, Yascha
  • Sandoval, Elena
  • Gerussi, Alessio
  • Karadeniz, Zehra
  • Gualtierotti, Roberta
  • Latiano, Anna
  • Goerg, Siegfried
  • Santoro, Luigi
  • Bacher, Petra
  • Koehler, Philipp
  • Tran, Florian
  • Zoller, Heinz
  • Binatti, Eleonora
  • Schulte, Eva C.
  • García Sánchez, Félix
  • Heidecker, Bettina
  • Palom, Adriana
  • Ludwig, Kerstin U.
  • Ramírez, Alfredo
  • Fernández, Javier
  • Téllez, Luis
  • Romero-Gómez, Manuel
  • Teles, Ana
  • Scarpini, Elio
  • Kildal, Anders Benjamin
  • Biondi, Andrea
  • Caballero-Garralda, Andrea
  • Ganna, Andrea
  • Gori, Andrea
  • Glück, Andreas
  • Lind, Andreas
  • Peyvandi, Flora
  • Gallego-Durán, Rocío
  • Tanck, Anja
  • Mesonero, Francisco
  • Helbig, Elisa T.
  • Hinney, Anke
  • Carreras Nolla, Anna
  • Fracanzani, Anna Ludovica
  • Peschuck, Anna
  • Cavallero, Annalisa
  • Dyrhol-Riise, Anne Ma
  • Ruello, Antonella
  • Julià, Antonio
  • Nieto Liñán, Rosa María
  • Schaefer, Marco
  • Muscatello, Antonio
  • Kurth, Florian
  • Ostadreza, Mahnoosh
  • Pesenti, Antonio
  • Voza, Antonio
  • Rando-Segura, Ariadna
  • Solier-López, Aurora
  • Schmidt, Axel
  • Cortes, Beatriz
  • Mateos, Beatriz
  • Rodríguez-Frías, Francisco
  • Carpani, Rossana
  • Nafría-Jiménez, Beatriz
  • Schaefer, Benedikt
  • Jensen, Björn
  • Intxausti, Maider
  • Blasi, Francesco
  • Bellinghausen, Carla
  • Maj, Carlo
  • Ferrando, Carlos
  • Horra, Carmen de la
  • Hanses, Frank
  • Quereda, Carmen
  • Mayer, Alena
  • Skurk, Carsten
  • Thibeault, Charlotte
  • Scollo, Chiara
  • Herr, Christian
  • Kogevinas, Manolis
  • Spinner, Christoph D.
  • Malvestiti, Francesco
  • Gassner, Christoph
  • Invernizzi, Pietro
  • Lange, Christoph
  • Hu, Cinzia
  • Morilla Romero de la Osa, R.
  • Paccapelo, Cinzia
  • Lehmann, Clara
  • Angelini, Claudio
  • Cappadona, Claudio
  • Azuure, Clinton
  • Riveiro-Barciela, Mar
  • COVICAT study group
  • Solligård, Erik
  • Covid-19 Aachen Study (COVAS)
  • Myhre, Ronny
  • Bianco, Cristiana
  • Badalamenti, Salvatore
  • Cea, Cristina
  • Müller, Fredrik
  • Hemmrich-Stanisak, Georg
  • Bellani, Giacomo
  • Grasselli, Giacomo
  • Pezzoli, Gianni
  • Costantino, Giorgio
  • Vadla, May Sissel
  • Albano, Giovanni
  • Niemi, Mari
  • Buti, María
  • Cardamone, Giulia
  • Lippert, Lena J.
  • Bellelli, Giuseppe
  • Citerio, Giuseppe
  • Foti, Giuseppe
  • Lamorte, Giuseppe
  • Matullo, Giuseppe
  • Baselli, Guido
  • Kurihara, Hayato
  • Neb, Holger
  • Duga, Stefano
  • Wacker, Eike M.
  • Gutiérrez-Stampa, María A.
  • Ciesek, Sandra
  • My, Ilaria
  • Kurth, Ingo
  • Hernández, Isabel
  • Pink, Isabell
  • Rojas, Itziar de
  • Galván-Femenia, Iván
  • Holter, Jan Cato
  • Bujanda, Luis
  • Afset, Jan Egil
  • Heyckendorf, Jan
  • Kässens, Jan
  • May, Sandra
  • Carrabba, Maria
  • Wienbrandt, Lars
  • Damås, Jan Kristian
  • Rybniker, Jan
  • Altmüller, Janine
  • Ampuero, Javier
  • Ceriotti, Ferruccio
  • Martín, Javier
  • Erdmann, Jeanette
  • Banales, Jesús M.
  • Badia, Joan Ramon
  • Bombace, Sara
  • Dopazo, Joaquín
  • Figuera Basso, Maria E.
  • Schneider, Jochen
  • Blandino Ortiz, Aaron
  • Bergan, Jonas
  • Hov, Johannes R.
  • Barretina, Jordi
  • Walter, Jörn
  • Hernández Quero, José
  • Goikoetxea-Aguirre, Josune
  • Delgado, Juan
  • Marsal, Sara
  • Guerrero, Juan M.
  • Fazaal, Julia
  • Casalone, Elisabetta
  • Kraft, Julia
  • Lenz, Tobias L.
  • Schröder, Julia
Given the highly variable clinical phenotype of Coronavirus disease 2019 (COVID-19), a deeper analysis of the host genetic contribution to severe COVID-19 is important to improve our understanding of underlying disease mechanisms. Here, we describe an extended genome-wide association meta-analysis of a well-characterized cohort of 3255 COVID-19 patients with respiratory failure and 12 488 population controls from Italy, Spain, Norway and Germany/Austria, including stratified analyses based on age, sex and disease severity, as well as targeted analyses of chromosome Y haplotypes, the human leukocyte antigen region and the SARS-CoV-2 peptidome. By inversion imputation, we traced a reported association at 17q21.31 to a ~0.9-Mb inversion polymorphism that creates two highly differentiated haplotypes and characterized the potential effects of the inversion in detail. Our data, together with the 5th release of summary statistics from the COVID-19 Host Genetics Initiative including non-Caucasian individuals, also identified a new locus at 19q13.33, including NAPSA, a gene which is expressed primarily in alveolar cells responsible for gas exchange in the lung., S.E.H. and C.A.S. partially supported genotyping through a philanthropic donation. A.F. and D.E. were supported by a grant from the German Federal Ministry of Education and COVID-19 grant Research (BMBF; ID:01KI20197); A.F., D.E. and F.D. were supported by the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). D.E. was supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the Computational Life Sciences funding concept (CompLS grant 031L0165). D.E., K.B. and S.B. acknowledge the Novo Nordisk Foundation (NNF14CC0001 and NNF17OC0027594). T.L.L., A.T. and O.Ö. were funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), project numbers 279645989; 433116033; 437857095. M.W. and H.E. are supported by the German Research Foundation (DFG) through the Research Training Group 1743, ‘Genes, Environment and Inflammation’. L.V. received funding from: Ricerca Finalizzata Ministero della Salute (RF-2016-02364358), Italian Ministry of Health ‘CV PREVITAL’—strategie di prevenzione primaria cardiovascolare primaria nella popolazione italiana; The European Union (EU) Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS- and for the project ‘REVEAL’; Fondazione IRCCS Ca’ Granda ‘Ricerca corrente’, Fondazione Sviluppo Ca’ Granda ‘Liver-BIBLE’ (PR-0391), Fondazione IRCCS Ca’ Granda ‘5permille’ ‘COVID-19 Biobank’ (RC100017A). A.B. was supported by a grant from Fondazione Cariplo to Fondazione Tettamanti: ‘Bio-banking of Covid-19 patient samples to support national and international research (Covid-Bank). This research was partly funded by an MIUR grant to the Department of Medical Sciences, under the program ‘Dipartimenti di Eccellenza 2018–2022’. This study makes use of data generated by the GCAT-Genomes for Life. Cohort study of the Genomes of Catalonia, Fundació IGTP (The Institute for Health Science Research Germans Trias i Pujol) IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya (ADE 10/00026); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) (2017-SGR 529). M.M. received research funding from grant PI19/00335 Acción Estratégica en Salud, integrated in the Spanish National RDI Plan and financed by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (European Regional Development Fund (FEDER)-Una manera de hacer Europa’). B.C. is supported by national grants PI18/01512. X.F. is supported by the VEIS project (001-P-001647) (co-funded by the European Regional Development Fund (ERDF), ‘A way to build Europe’). Additional data included in this study were obtained in part by the COVICAT Study Group (Cohort Covid de Catalunya) supported by IsGlobal and IGTP, European Institute of Innovation & Technology (EIT), a body of the European Union, COVID-19 Rapid Response activity 73A and SR20-01024 La Caixa Foundation. A.J. and S.M. were supported by the Spanish Ministry of Economy and Competitiveness (grant numbers: PSE-010000-2006-6 and IPT-010000-2010-36). A.J. was also supported by national grant PI17/00019 from the Acción Estratégica en Salud (ISCIII) and the European Regional Development Fund (FEDER). The Basque Biobank, a hospital-related platform that also involves all Osakidetza health centres, the Basque government’s Department of Health and Onkologikoa, is operated by the Basque Foundation for Health Innovation and Research-BIOEF. M.C. received Grants BFU2016-77244-R and PID2019-107836RB-I00 funded by the Agencia Estatal de Investigación (AEI, Spain) and the European Regional Development Fund (FEDER, EU). M.R.G., J.A.H., R.G.D. and D.M.M. are supported by the ‘Spanish Ministry of Economy, Innovation and Competition, the Instituto de Salud Carlos III’ (PI19/01404, PI16/01842, PI19/00589, PI17/00535 and GLD19/00100) and by the Andalussian government (Proyectos Estratégicos-Fondos Feder PE-0451-2018, COVID-Premed, COVID GWAs). The position held by Itziar de Rojas Salarich is funded by grant FI20/00215, PFIS Contratos Predoctorales de Formación en Investigación en Salud. Enrique Calderón’s team is supported by CIBER of Epidemiology and Public Health (CIBERESP), ‘Instituto de Salud Carlos III’. J.C.H. reports grants from Research Council of Norway grant no 312780 during the conduct of the study. E.S. reports grants from Research Council of Norway grant no. 312769. The BioMaterialBank Nord is supported by the German Center for Lung Research (DZL), Airway Research Center North (ARCN). The BioMaterialBank Nord is member of popgen 2.0 network (P2N). P.K. Bergisch Gladbach, Germany and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany. He is supported by the German Federal Ministry of Education and Research (BMBF). O.A.C. is supported by the German Federal Ministry of Research and Education and is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy—CECAD, EXC 2030–390661388. The COMRI cohort is funded by Technical University of Munich, Munich, Germany. This work was supported by grants of the Rolf M. Schwiete Stiftung, the Saarland University, BMBF and The States of Saarland and Lower Saxony. K.U.L. is supported by the German Research Foundation (DFG, LU-1944/3-1). Genotyping for the BoSCO study is funded by the Institute of Human Genetics, University Hospital Bonn. F.H. was supported by the Bavarian State Ministry for Science and Arts. Part of the genotyping was supported by a grant to A.R. from the German Federal Ministry of Education and Research (BMBF, grant: 01ED1619A, European Alzheimer DNA BioBank, EADB) within the context of the EU Joint Programme—Neurodegenerative Disease Research (JPND). Additional funding was derived from the German Research Foundation (DFG) grant: RA 1971/6-1 to A.R. P.R. is supported by the DFG (CCGA Sequencing Centre and DFG ExC2167 PMI and by SH state funds for COVID19 research). F.T. is supported by the Clinician Scientist Program of the Deutsche Forschungsgemeinschaft Cluster of Excellence ‘Precision Medicine in Chronic Inflammation’ (EXC2167). C.L. and J.H. are supported by the German Center for Infection Research (DZIF). T.B., M.M.B., O.W. und A.H. are supported by the Stiftung Universitätsmedizin Essen. M.A.-H. was supported by Juan de la Cierva Incorporacion program, grant IJC2018-035131-I funded by MCIN/AEI/10.13039/501100011033. E.C.S. is supported by the Deutsche Forschungsgemeinschaft (DFG; SCHU 2419/2-1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

  • Gil-Gómez, Antonio
  • Rojas, Ángela
  • García-Lozano, María del Rosario
  • Muñoz-Hernández, Rocío
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas
  • Montero-Vallejo, Rocío
  • Gato, Sheila
  • Gallego, Javier
  • Francés, Rubén
  • Soriano, Germán
  • Ampuero, Javier
  • Romero-Gómez, Manuel
A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and cirrhosis. In this study, we aimed to evaluate the prognosis of cirrhotic patients harboring this variant. We performed a retrospective analysis on 483 prospectively recruited patients from four different hospitals in Spain, followed-up for at least 5 years. We collected clinical, demographic, and biochemical data, and we performed a genotyping analysis for common variants previously associated with liver disease risk (HSD17B13 rs72613567:TA and PNPLA3 rs738409). Patients homozygous for the TA allele showed a higher MELD score (p = 0.047), Child−Turcotte−Pugh score (p = 0.014), and INR levels (p = 0.046), as well as decreased albumin (p = 0.004) at baseline. After multivariate analysis, patients with the “protective” variant indeed had an increased risk of hepatic decompensation [aHR 2.37 (1.09−5.06); p = 0.029] and liver-related mortality [aHR 2.32 (1.20−4.46); p = 0.012]. Specifically, these patients had an increased risk of developing ascites (Log-R 11.6; p < 0.001), hepatic encephalopathy (Log-R 10.2; p < 0.01), and higher mortality (Log-R 14.1; p < 0.001) at 5 years of follow-up. Interactions with the etiology of the cirrhosis and with the variant rs738409 in PNPLA3 are also described. These findings suggest that the variant rs72613567:TA in HSD17B13 has no protective effect, but indeed increases the risk of decompensation and death in patients with advanced chronic liver disease., The research leading to these results received funding from Consejería de Salud de la Junta de Andalucía under grant agreements PE-0451-2018 and P20_01075 del programa PAIDI 2020 and from Instituto de Salud Carlos III, Ministerio de Ciencia y Competitividad under grant agreements PI19/01404 and PI19/00589. This research was also funded by European project LITMUS 777377 from Horizon 2020; a contract with fellowships from Consejería de Salud y Familias, Junta de Andalucía, supporting Antonio Gil-Gómez (RH-122-2020) and Angela Rojas (RH-002-2021); grant agreements PFIS FI20/00201 and IFI18/00041 from Instituto de Salud Carlos III to support Sheila Gato and Rocio Montero-Vallejo; and by support from Talento Doctores (PID Junta Andalucía, DOC_00866) to Rocío Muñoz-Hernández., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography

  • Liang, Jia-xu
  • Ampuero, Javier
  • Niu, Hao
  • Imajo, Kento
  • Noureddin, Mazen
  • Behari, Jaideep
  • Lee, Dae Ho
  • Ehman, Richard L.
  • Rorsman, Fredrik
  • Vessby, Johan
  • Lacalle, Juan R.
  • Mózes, Ferenc E.
  • Pavlides, Michael
  • Anstee, Quentin M.
  • Harrison, Stephen A.
  • Castell, Javier
  • Loomba, Rohit
  • Romero-Gómez, Manuel
  • LITMUS Consortium Investigators
© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)., [Background & Aims] We conducted an individual patient data meta-analysis to establish stiffness cut-off values for magnetic resonance elastography (MRE) in staging liver fibrosis and to assess potential confounding factors., [Methods] A systematic review of the literature identified studies reporting MRE data in patients with NAFLD. Data were obtained from the corresponding authors. The pooled diagnostic cut-off value for the various fibrosis stages was determined in a two-stage meta-analysis. Multilevel modelling methods were used to analyse potential confounding factors influencing the diagnostic accuracy of MRE in staging liver fibrosis., [Results] Eight independent cohorts comprising 798 patients were included in the meta-analysis. The area under the receiver operating characteristic curve (AUROC) for MRE in detecting significant fibrosis was 0.92 (sensitivity, 79%; specificity, 89%). For advanced fibrosis, the AUROC was 0.92 (sensitivity, 87%; specificity, 88%). For cirrhosis, the AUROC was 0.94 (sensitivity, 88%, specificity, 89%). Cut-offs were defined to explore concordance between MRE and histopathology: ≥F2, 3.14 kPa (pretest probability, 39.4%); ≥F3, 3.53 kPa (pretest probability, 24.1%); and F4, 4.45 kPa (pretest probability, 8.7%). In generalized linear mixed model analysis, histological steatohepatitis with higher inflammatory activity (odds ratio 2.448, 95% CI 1.180–5.079, p <0.05) and high gamma-glutamyl transferase (GGT) concentration (>120U/L) (odds ratio 3.388, 95% CI 1.577–7.278, p <0.01] were significantly associated with elevated liver stiffness, and thus affecting accuracy in staging early fibrosis (F0–F1). Steatosis, as measured by magnetic resonance imaging proton density fat fraction, and body mass index(BMI) were not confounders., [Conclusions] MRE has excellent diagnostic performance for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Elevated inflammatory activity and GGT level may lead to overestimation of early liver fibrosis, but anthropometric measures such as BMI or the degree of steatosis do not., [Impact and implications] This individual patient data meta-analysis of eight international cohorts, including 798 patients, demonstrated that MRE achieves excellent diagnostic accuracy for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Cut-off values (significant fibrosis, 3.14 kPa; advanced fibrosis, 3.53 kPa; and cirrhosis, 4.45 kPa) were established. Elevated inflammatory activity and gamma-glutamyltransferase level may affect the diagnostic accuracy of MRE, leading to overestimation of liver fibrosis in early stages. We observed no impact of diabetes, obesity, or any other metabolic disorder on the diagnostic accuracy of MRE., We would like to thank LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) project for supporting this research. The LITMUS study is funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking under grant agreement 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA; efpia.edu). RL receives funding support from NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK106419, R01DK121378, R01DK124318, and P30DK120515), NHLBI (P01HL147835), and NIAAA (U01AA029019). QMA is a coordinator of the LITMUS consortium and a Newcastle NIHR Biomedical Research Centre investigator. MP acknowledges support from the Oxford NIHR Biomedical Research Centre. RLE acknowledges support from the National Institutes of Health (grant R37 EB001981). DHL received a grant from KHIDI (Korea Health Industry Development Institute) (HI14C1135), funded by the Ministry of Health and Welfare, Korea. JB acknowledges funding support from NCATS (4UH3TR003289), NCI 1R01CA255809, and NIAAA (5U01AA026978)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study

  • Vali, Yasaman
  • Lee, Jenny
  • Boursier, Jerome
  • Petta, Salvatore
  • Wonders, Kristy
  • Tiniakos, Dina
  • Bedossa, Pierre
  • Geier, Andreas
  • Francque, Sven
  • Allison, Mike
  • Papatheodoridis, Georgios
  • Cortez-Pinto, Helena
  • Pais, Raluca
  • Dufour, Jean-François
  • Leeming, Diana Julie
  • Harrison, Stephen A.
  • Chen, Yu
  • Cobbold, Jeremy F.
  • Pavlides, Michael
  • Holleboom, Adriaan G.
  • Yki-Jarvinen, Hannele
  • Crespo, Javier
  • Karsdal, Morten
  • Ostroff, Rachel
  • Zafarmand, Mohammad Hadi
  • Torstenson, Richard
  • Duffin, Kevin
  • Yunis, Carla
  • Brass, Clifford
  • Ekstedt, Mattias
  • Aithal, Guruprasad P.
  • Schattenberg, Jörn M.
  • Bugianesi, Elisabetta
  • Romero-Gómez, Manuel
  • Ratziu, Vlad
  • Anstee, Quentin M.
  • Bossuyt, Patrick M.
  • on behalf of theLiver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium investigators
© 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license., [Background] The reference standard for detecting non-alcoholic steatohepatitis (NASH) and staging fibrosis—liver biopsy—is invasive and resource intensive. Non-invasive biomarkers are urgently needed, but few studies have compared these biomarkers in a single cohort. As part of the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, we aimed to evaluate the diagnostic accuracy of 17 biomarkers and multimarker scores in detecting NASH and clinically significant fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) and identify their optimal cutoffs as screening tests in clinical trial recruitment., [Methods] This was a comparative diagnostic accuracy study in people with biopsy-confirmed NAFLD from 13 countries across Europe, recruited between Jan 6, 2010, and Dec 29, 2017, from the LITMUS metacohort of the prospective European NAFLD Registry. Adults (aged ≥18 years) with paired liver biopsy and serum samples were eligible; those with excessive alcohol consumption or evidence of other chronic liver diseases were excluded. The diagnostic accuracy of the biomarkers was expressed as the area under the receiver operating characteristic curve (AUC) with liver histology as the reference standard and compared with the Fibrosis-4 index for liver fibrosis (FIB-4) in the same subgroup. Target conditions were the presence of NASH with clinically significant fibrosis (ie, at-risk NASH; NAFLD Activity Score ≥4 and F≥2) or the presence of advanced fibrosis (F≥3), analysed in all participants with complete data. We identified thres holds for each biomarker for reducing the number of biopsy-based screen failures when recruiting people with both NASH and clinically significant fibrosis for future trials., [Findings] Of 1430 participants with NAFLD in the LITMUS metacohort with serum samples, 966 (403 women and 563 men) were included after all exclusion criteria had been applied. 335 (35%) of 966 participants had biopsy-confirmed NASH and clinically significant fibrosis and 271 (28%) had advanced fibrosis. For people with NASH and clinically significant fibrosis, no single biomarker or multimarker score significantly reached the predefined AUC 0·80 acceptability threshold (AUCs ranging from 0·61 [95% CI 0·54–0·67] for FibroScan controlled attenuation parameter to 0·81 [0·75–0·86] for SomaSignal), with accuracy mostly similar to FIB-4. Regarding detection of advanced fibrosis, SomaSignal (AUC 0·90 [95% CI 0·86–0·94]), ADAPT (0·85 [0·81–0·89]), and FibroScan liver stiffness measurement (0·83 [0·80–0·86]) reached acceptable accuracy. With 11 of 17 markers, histological screen failure rates could be reduced to 33% in trials if only people who were marker positive had a biopsy for evaluating eligibility. The best screening performance for NASH and clinically significant fibrosis was observed for SomaSignal (number needed to test [NNT] to find one true positive was four [95% CI 4–5]), then ADAPT (six [5–7]), MACK-3 (seven [6–8]), and PRO-C3 (nine [7–11])., [Interpretation] None of the single markers or multimarker scores achieved the predefined acceptable AUC for replacing biopsy in detecting people with both NASH and clinically significant fibrosis. However, several biomarkers could be applied in a prescreening strategy in clinical trial recruitment. The performance of promising markers will be further evaluated in the ongoing prospective LITMUS study cohort., This study was done as part of the LITMUS project, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 777377). This Joint Undertaking receives support from the EU Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study

  • Lee, Jenny
  • Westphal, Max
  • Vali, Yasaman
  • Boursier, Jerome
  • Petta, Salvatorre
  • Ostroff, Rachel
  • Alexander, Leigh
  • Chen, Yu
  • Fournier, Celine
  • Geier, Andreas
  • Francque, Sven
  • Wonders, Kristy
  • Tiniakos, Dina
  • Bedossa, Pierre
  • Allison, Mike
  • Papatheodoridis, Georgios
  • Cortez-Pinto, Helena
  • Pais, Raluca
  • Dufour, Jean-François
  • Leeming, Diana Julie
  • Harrison, Stephen
  • Cobbold, Jeremy
  • Holleboom, Adriaan G.
  • Yki-Järvinen, Hannele
  • Crespo, Javier
  • Ekstedt, Mattias
  • Aithal, Guruprasad P.
  • Bugianesi, Elisabetta
  • Romero-Gómez, Manuel
  • Torstenson, Richard
  • Karsdal, Morten
  • Yunis, Carla27;
  • Schattenberg, Jörn M.
  • Schuppan, Detlef
  • Ratziu, Vlad
  • Brass, Clifford
  • Duffin, Kevin
  • Zwinderman, Koos
  • Pavlides, Michael
  • Anstee, Quentin M.
  • Bossuyt, Patrick M.
  • LITMUS investigators
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal., [Background and Aims] Detecting NASH remains challenging, while at-risk NASH (steatohepatitis and F≥ 2) tends to progress and is of interest for drug development and clinical application. We developed prediction models by supervised machine learning techniques, with clinical data and biomarkers to stage and grade patients with NAFLD., [Approach and Results] Learning data were collected in the Liver Investigation: Testing Marker Utility in Steatohepatitis metacohort (966 biopsy-proven NAFLD adults), staged and graded according to NASH CRN. Conditions of interest were the clinical trial definition of NASH (NAS ≥ 4;53%), at-risk NASH (NASH with F ≥ 2;35%), significant (F ≥ 2;47%), and advanced fibrosis (F ≥ 3;28%). Thirty-five predictors were included. Missing data were handled by multiple imputations. Data were randomly split into training/validation (75/25) sets. A gradient boosting machine was applied to develop 2 models for each condition: clinical versus extended (clinical and biomarkers). Two variants of the NASH and at-risk NASH models were constructed: direct and composite models. Clinical gradient boosting machine models for steatosis/inflammation/ballooning had AUCs of 0.94/0.79/0.72. There were no improvements when biomarkers were included. The direct NASH model produced AUCs (clinical/extended) of 0.61/0.65. The composite NASH model performed significantly better (0.71) for both variants. The composite at-risk NASH model had an AUC of 0.83 (clinical and extended), an improvement over the direct model. Significant fibrosis models had AUCs (clinical/extended) of 0.76/0.78. The extended advanced fibrosis model (0.86) performed significantly better than the clinical version (0.82)., [Conclusions] Detection of NASH and at-risk NASH can be improved by constructing independent machine learning models for each component, using only clinical predictors. Adding biomarkers only improved the accuracy of fibrosis., The LITMUS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. Sven Francque holds a senior clinical investigator fellowship from the Research Foundation Flanders (FWO) (1802154N)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity

  • Tedbury, Philip R.
  • Manfredi, Candela
  • Degenhardt, Frauke
  • Conway, Joseph
  • Horwath, Michael C.
  • McCracken, Courtney
  • Sorscher, Adam J.
  • Moreau, Sandy
  • Wright, Christine
  • Edwards, Carolina
  • Brewer, Jo
  • Guarner, Jeannette
  • Wit, Emmie de
  • Williamson, Brandi N.
  • Suthar, Mehul S.
  • Ong, Yee T.
  • Roback, John D.
  • Alter, David N.
  • Holter, Jan Cato
  • Karlsen, Tom H.
  • Sacchi, Nicoletta
  • Romero-Gómez, Manuel
  • Invernizzi, Pietro
  • Fernández, Javier
  • Buti, María
  • Albillos, Agustín
  • Julià, Antonio
  • Valenti, Luca
  • Asselta, Rosanna
  • Banales, Jesús M.
  • Bujanda, Luis
  • Cid, Rafael de
  • Franke, André
  • Severe COVID-19 GWAS group
  • Horra, Carmen de la
  • Maya-Miles, Douglas
  • Calderón, Enrique J.
  • Medrano, Francisco Javier
  • Ampuero, Javier
  • Martín, Javier
  • Dopazo, Joaquín
  • Delgado, Juan
  • Guerrero, Juan M.
  • Acosta-Herrera, Marialbert
  • Gallego-Durán, Rocío
  • Morilla Romero de la Osa, R.
  • Friaza Patiño, Vicente
  • Sarafianos, Stefan G.
  • Hong, Jeong S.
  • Sorscher, Eric J.
  • Ehrhardt, Annette
Patients with cystic fibrosis (CF) exhibit pronounced respiratory damage and were initially considered among those at highest risk for serious harm from SARS-CoV-2 infection. Numerous clinical studies have subsequently reported that individuals with CF in North America and Europe—while susceptible to severe COVID-19—are often spared from the highest levels of virus-associated mortality. To understand features that might influence COVID-19 among patients with cystic fibrosis, we studied relationships between SARS-CoV-2 and the gene responsible for CF (i.e., the cystic fibrosis transmembrane conductance regulator, CFTR). In contrast to previous reports, we found no association between CFTR carrier status (mutation heterozygosity) and more severe COVID-19 clinical outcomes. We did observe an unexpected trend toward higher mortality among control individuals compared with silent carriers of the common F508del CFTR variant—a finding that will require further study. We next performed experiments to test the influence of homozygous CFTR deficiency on viral propagation and showed that SARS-CoV-2 production in primary airway cells was not altered by the absence of functional CFTR using two independent protocols. On the contrary, experiments performed in vitro strongly indicated that virus proliferation depended on features of the mucosal fluid layer known to be disrupted by absent CFTR in patients with CF, including both low pH and increased viscosity. These results point to the acidic, viscous, and mucus-obstructed airways in patients with cystic fibrosis as unfavorable for the establishment of coronaviral infection. Our findings provide new and important information concerning relationships between the CF clinical phenotype and severity of COVID-19., This work was supported by the Italian Ministry of Health (Ministero della Salute) [Ricerca Finalizzata RF-2016-02364358]; Fondazione IRCCS Ca′ Granda Ospedale Maggiore Policlinico, Ricerca corrente; Fondazione IRCCS Ca′ Granda core COVID-19 Biobank [RC100017A]; “Liver BIBLE” [PR-0391]; and Innovative Medicines Initiative 2 joint undertaking of the European Union (EU) Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations Programme Horizon 2020 [under grant agreement No. 777377] for the project LITMUS and the European Union, programme “Photonics” [under grant agreement 101016726] to LV. JCH was funded by the Research Council of Norway [grant no 312780] and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. AF was supported by a grant from the German Federal Ministry of Education and Research [01KI20197]. This work was also funded by a generous philanthropic donation from Banca Intesa San Paolo to RA. This study makes use of data generated by the GCATI Genomes for Life. Cohort study of the Genomes of Catalonia from Institut Germans Trias I Pujol (IGTP); IGTP is part of the CERCA Program/Generalitat de Catalunya. GCAT is supported by Acción de Dinamización del ISCIII-MINECO and the Ministry of Health of the Generalitat of Catalunya [ADE 10/00026], with additional support by the Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) [2017-SGR 529], National Grant [PI18/01512], and VEIS project [001-P-001647], co-funded by European Regional Development Fund (ERDF), “A way to build Europe.” EdW and BNW were supported by the Intramural Research Program, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). PRT and SGS received funding from NIH NIAID [R01 AI167356]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom

  • Funuyet-Salas, Jesús
  • Martín-Rodríguez, Agustín
  • Pérez-San-Gregorio, María Ángeles
  • Vale, Luke
  • Robinson, Tomos
  • Anstee, Quentin M.
  • Romero-Gómez, Manuel
[Background] It is unclear what biopsychosocial factors influence the impact of NAFLD on health-related quality of life (HRQoL), and if these factors are equally important predictors between different nationalities., [Methods] HRQoL (CLDQ) was measured in both Southern European (Spain, n = 513) and Northern European (United Kingdom -UK-, n = 224) cohorts of patients with NAFLD in this cross-sectional study. For each cohort, participant data were recorded on histological grade of steatohepatitis, stage of fibrosis and biopsychosocial variables. Regression analysis was used to explore which of these variables predicted HRQoL. Moderated mediation models were conducted using SPSS PROCESS v3.5 macro., [Results] Participants with severe fibrosis reported more fatigue, systemic symptoms and worry, and lower HRQoL than those with none/mild fibrosis, regardless of place of origin. In addition, body mass index (BMI) and gender were found to be significant predictors of HRQoL in both Spanish and UK participants. Female gender was associated with worse emotional function, higher BMI and more fatigue, which predicted lower participants’ HRQoL. UK participants showed more systemic symptoms and worry than Spanish participants, regardless of liver severity. The negative effects of gender on HRQoL through emotional function, BMI and fatigue were reported to a greater degree in UK than in Spanish participants., [Conclusions] UK participants showed a greater impairment in HRQoL as compared to Spanish participants. Higher fibrosis stage predicted lower HRQoL, mainly in the Spanish cohort. Factors such as female gender or higher BMI contributed to the impact on HRQoL in both cohorts of patients and should be considered in future multinational intervention studies in NAFLD., This study was funded by the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) consortium which is funded by the Innovative Medicines Initiative (IMI2) Program of the European Union under Grant Agreement 777377, which receives funding from the EU Horizon 2020 programme and European Federation of Pharmaceutical Industries and Associations (EFPIA). The European NAFLD Registry and the Newcastle NIHR Biomedical Research Centre provided support so that this project could be carried out in Newcastle, UK. This study was also funded by the Fondo Europeo de Desarrollo Regional (FEDER)/Ministerio de Ciencia e Innovación—Agencia Estatal de Investigación in the form of a grant to JF-S, MAP-S-G, and AM-R [project PSI2017-83365-P], the Ministerio de Educación y Formación Profesional in the form of a grant to JF-S [project FPU16/03146], and the Gilead Sciences, Inc. in the form of an unrestricted grant to MR-G; this funding was provided so that this study could be carried out in Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe

  • Lazarus, Jeffrey V.
  • Ekstedt, Mattias
  • Marchesini, Giulio
  • Mullen, Jillian
  • Novak, Katja
  • Pericàs, Juan M.
  • Roel, Elena
  • Romero-Gómez, Manuel
  • Ratziu, Vlad
  • Tacke, Frank
  • Cortez-Pinto, Helena
  • Anstee, Quentin M.
Non-alcoholic fatty liver disease (NAFLD) is a growing public health problem worldwide and has become an important field of biomedical inquiry. We aimed to determine whether European countries have mounted an adequate public health response to NAFLD and non-alcoholic steatohepatitis (NASH)., Financial support for this research was provided by the EASL International Liver Foundation through grants from Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc. JVL is a Miguel Servet-funded researcher at ISGlobal, Hospital Clínic, University of Barcelona. QMA and VR are members of the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413. QMA, VR, HCP, ME, MRG, HCP are members of the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium funded by the IMI2 Program of the European Union under Grant Agreement 777377. QMA is a Newcastle NIHR Biomedical Research Centre investigator., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Impact of the COVID-19 pandemic on the care and outcomes of people with NAFLD-related cirrhosis

  • Rivera-Esteban, Jesús
  • Manzano-Nuñez, Ramiro
  • Broquetas, Teresa
  • Serra-Matamala, Isabel
  • Bassegoda, Octavi
  • Soriano-Varela, Agnès
  • Espín, Gemma
  • Castillo, Joaquín
  • Bañares, Juan
  • Carrión Rodríguez, José Antonio
  • Ginès, Pere
  • Graupera, Isabel
  • Pericàs, Juan
Background & aims: The COVID-19 pandemic has had a major negative impact on health systems and many chronic diseases globally. We aimed to evaluate the impact of the first year of the pandemic on the outcomes of people with NAFLD cirrhosis. Methods: We conducted a before-after study in four University hospitals in Catalonia, Spain. Study subperiods were divided into Pre-pandemic (March/2019-February/2020) vs. Pandemic (March/2020-February/2021). The primary outcome was the rate of first liver-related event (LRE). Overall clinical outcomes (LREs plus cardiovascular plus all-cause mortality) were also assessed. Results: A total of 354 patients were included, all of whom were compensated at the beginning of the study period; 83 individuals (23.5%) had a history of prior hepatic decompensation. Mean age was 67.3 years and 48.3% were female. Median BMI was 31.2 kg/m2 and type 2 diabetes was present in 72.8% of patients. The rates of first LRE in the Pre-pandemic and Pandemic periods were 7.4% and 11.3% (p = 0.12), respectively. Whilst the rate of overall events was significantly higher in the Pandemic period (9.9% vs. 17.8%; p = 0.009), this was strongly associated with COVID-19-related deaths. The rate of worsened metabolic status was significantly higher in the Pandemic period (38.4% vs. 46.1%; p = 0.041), yet this was not associated with the risk of first LRE during the Pandemic period, whereas type 2 diabetes (odds ratio [OR] 3.77; 95% CI 1.15-12.32; p = 0.028), albumin <4 g/L (OR 4.43; 95% CI 1.76-11.17; p = 0.002) and Fibrosis-4 score >2.67 (OR 15.74; 95% CI 2.01-123.22; p = 0.009) were identified as risk factors in the multivariable analysis. Conclusion: Overall, people with NAFLD cirrhosis did not present poorer liver-related outcomes during the first year of the pandemic. Health system preparedness seems key to ensure that people with NAFLD cirrhosis receive appropriate care during health crises.Lay summary: Mobility restrictions and social stress induced by the COVID-19 pandemic have led to increased alcohol drinking and worsened metabolic control (e.g., weight gain, poor control of diabetes) in a large proportion of the population in many countries. We aimed to analyze whether people with cirrhosis due to non-alcoholic fatty liver disease, who are particularly vulnerable to such lifestyle modifications, were significantly impacted during the first year of the pandemic. We compared the clinical situation of 354 patients one year before the pandemic and one year after. We found that although metabolic control was indeed worse after the first year of the pandemic and patients presented worse clinical outcomes, the latter was mostly due to non-liver causes, namely COVID-19 itself. Moreover, the care provided to these patients did not worsen during the first year of the pandemic., TB has received educational and research support from Gilead and Abbvie. JMP reports having received consulting fees from Boehringer Ingelheim and Novo Nordisk. He has received speaking fees from Gilead, and travel expenses from Gilead, Rubió, Pfizer, Astellas, MSD, CUBICIN, and Novo Nordisk. He has received educational and research support from Gilead, Pfizer, Astellas, Accelerate, Novartis, Abbvie, ViiV, and MSD, and funds from European Commission/EFPIA IMI2 853966-2, IMI2 777377, H2020 847989, and ISCIII PI19/01898. Other authors: nothing to disclose. None of the authors have any personal conflict with regards to the present manuscript.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality

  • Nakanishi, Tomoko|||0000-0001-9510-5646
  • Pigazzini, Sara
  • Degenhardt, Frauke|||0000-0001-7516-3179
  • Cordioli, Mattia|||0000-0002-4872-0520
  • Butler-Laporte, Guillaume|||0000-0001-5388-0396
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Nafria-Jimenez, Beatriz|||0000-0002-4698-5680
  • Bouysran, Youssef|||0000-0003-1368-6550
  • Niemi, Mari
  • Palom, Adriana|||0000-0002-0130-1302
  • Ellinghaus, David|||0000-0002-4332-6110
  • Khan, Atlas
  • Martínez-Bueno, Manuel
  • Rolker, Selina
  • Amitano, Sara
  • Roade, Luisa|||0000-0002-8160-9613
  • Fava, Francesca
  • Spinner, Christoph D.|||0000-0002-3875-5367
  • Prati, Daniele|||0000-0002-2281-7498
  • Bernardo, D.|||0000-0002-2843-6696
  • Garcia, Federico
  • Darcis, Gilles|||0000-0001-8192-1351
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Holter, Jan Cato
  • Banales, Jesus|||0000-0002-5224-2373
  • Frithiof, Robert
  • Kiryluk, Krzysztof|||0000-0002-5047-6715
  • Duga, Stefano
  • Asselta, Rosanna
  • Pereira, Alexandre C.
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Bujanda, Luis|||0000-0002-4353-9968
  • Hov, Johannes R.|||0000-0002-5900-8096
  • Migeotte, Isabelle
  • Renieri, Alessandra|||0000-0002-0846-9220
  • Planas, Anna Maria|||0000-0002-6147-1880
  • Ludwig, Kerstin U.|||0000-0002-8541-2519
  • Buti, Maria|||0000-0002-0732-3078
  • Rahmouni, Souad
  • Alarcón-Riquelme, Marta E.|||0000-0002-7632-4154
  • Schulte, Eva C.|||0000-0003-3105-5672
  • Franke, Andre|||0000-0003-1530-5811
  • Karlsen, Tom H.
  • Valenti, Luca|||0000-0001-8909-0345
  • Zeberg, Hugo
  • Richards, J. Brent
  • Ganna, Andrea|||0000-0002-8147-240X
There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes, A retrospective case-control study

  • Bañares, Juan|||0000-0002-1966-1947
  • Manzano-Nuñez, Ramiro|||0000-0001-7444-9634
  • Prió, Alba
  • Rivera Esteban, Jesús|||0000-0003-4357-8817
  • Camps-Relats, Laura
  • Villarejo Jiménez, Ana|||0009-0005-7996-9387
  • Ruiz-Ortega, Lourdes|||0000-0003-3636-3367
  • Pons Delgado, Mònica|||0000-0002-0985-3320
  • Ciudin, Andreea|||0000-0001-5622-0203
  • Salcedo, Maria-Teresa|||0000-0002-4822-5060
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Pericàs, Juan M.|||0000-0002-3645-3293
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in developed countries, with its incidence growing parallel to the epidemics of obesity and type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are becoming a cornerstone in the management of cardiovascular health and some studies suggest the potential role in NAFLD. However, patients under treatment with SGLT2i are at risk of developing genitourinary fungal infections (GFIs). Moreover, both NAFLD and SGLT2i have a strong influence on the immune system, and therefore the risk of infections other than GFIs could be increased in NAFLD patients treated with SGLT2i. We aimed to examine the possible association of SGLT2i with infections and hepatic outcomes in NAFLD patients. We conducted a case-control study including NAFLD patients with T2DM visited at the Liver Unit outpatient clinic from 2016 to 2021 with a minimum follow-up of 6 months by selecting 65 patients receiving SGLT2i and 130 matched patients with other types of antidiabetic treatment. During follow-up, GFIs were significantly higher in the SGLT2i group (15.4% vs. 3.8%; p=0.008), whereas there were no differences in the occurrence of overall infections (41.5% vs. 30%; p=0.1) nor in other types of specific infections. In the multivariable analysis, treatment with SGLT2i was not independently associated with higher odds of overall infection. On the other hand, SGLT2i patients showed a significantly lower incidence of hepatic events (1.5% vs. 10.7%; p=0.02). There were no significant different in all-cause mortality between cases and controls. NAFLD patients with T2DM receiving SGLT2i more frequently presented GFIs, whereas the incidence of other types of infections was not found to be higher than in other patients with NAFLD and T2DM treated with other drugs. Moreover, SGLT2i-treated patients had a lower occurrence of hepatic events. Further studies are warranted to validate our data.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients

  • Gil-Gómez, Antonio
  • Rojas, Ángela|||0000-0003-0853-4800
  • García-Lozano, María R.
  • Muñoz-Hernández, Rocío
  • Gallego-Durán, Rocío
  • Maya-Miles, Douglas|||0000-0002-0669-6526
  • Montero-Vallejo, Rocío
  • Gato, Sheila
  • Gallego, Javier
  • Francés, Rubén
  • Soriano, German|||0000-0002-9267-6811
  • Ampuero, Javier|||0000-0002-8332-2122
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced fibrosis and cirrhosis. In this study, we aimed to evaluate the prognosis of cirrhotic patients harboring this variant. We performed a retrospective analysis on 483 prospectively recruited patients from four different hospitals in Spain, followed-up for at least 5 years. We collected clinical, demographic, and biochemical data, and we performed a genotyping analysis for common variants previously associated with liver disease risk (HSD17B13 rs72613567:TA and PNPLA3 rs738409). Patients homozygous for the TA allele showed a higher MELD score (p = 0.047), Child-Turcotte-Pugh score (p = 0.014), and INR levels (p = 0.046), as well as decreased albumin (p = 0.004) at baseline. After multivariate analysis, patients with the "protective" variant indeed had an increased risk of hepatic decompensation [aHR 2.37 (1.09-5.06); p = 0.029] and liver-related mortality [aHR 2.32 (1.20-4.46); p = 0.012]. Specifically, these patients had an increased risk of developing ascites (Log-R 11.6; p < 0.001), hepatic encephalopathy (Log-R 10.2; p < 0.01), and higher mortality (Log-R 14.1; p < 0.001) at 5 years of follow-up. Interactions with the etiology of the cirrhosis and with the variant rs738409 in PNPLA3 are also described. These findings suggest that the variant rs72613567:TA in HSD17B13 has no protective effect, but indeed increases the risk of decompensation and death in patients with advanced chronic liver disease.
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

  • Martínez Arranz, Ibón
  • Bruzzone, Chiara
  • Noureddin, Mazen
  • Gil Redondo, Rubén
  • Mincholé, Itziar
  • Bizkarguenaga, Maider
  • Arretxe, Enara
  • Iruarrizaga Lejarreta, Marta
  • Fernández Ramos, David
  • Lopitz Otsoa, Fernando
  • Mayo, Rebeca
  • Embade, Nieves
  • Newberry, Elizabeth
  • Mittendorf, Bettina
  • Izquierdo Sánchez, Laura
  • Smid, Vaclav
  • Arnold, Jorge
  • Iruzubieta, Paula
  • Pérez Castaño, Ylenia
  • Krawczyk, Marcin
  • Marigorta, Urko M.
  • Morrison, Martine C.
  • Kleemann, Robert
  • Martín Duce, Antonio|||0000-0001-8751-9224
  • Hayardeny, Liat
  • Vitek, Libor
  • Bruha, Radan
  • Aller de la Fuente, Rocío
  • Crespo, Javier
  • Romero Gómez, Manuel
  • Banales, Jesús M.
  • Arrese, Marco
  • Cusi, Kenneth
  • Bugianesi, Elisabetta
  • Klein, Samuel
  • Lu, Shelly C.
  • Anstee, Quentin M.
  • Millet, Oscar
  • Davidson, Nicholas O.
  • Alonso, Cristina
  • Mato, José M.
14 p., Background and aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification., National Institutes of Health (USA), Netherlands Organization for Applied Scientific Research (TNO) (Países Bajos), Newcastle NIHR Biomedical Research Center, Czech Ministry of Health, Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), Departamento de Industria, Transición Energética y Sostenibilidad (Gobierno Vasco), Fundación La Caixa, Unión Europea, Fondo Nacional de Desarrollo Científico y Tecnológico (Fondecyt) (Chile), Comisión Nacional de Investigación, Ciencia y Tecnología (Chile), Agencia Nacional de Investigación y Desarrollo (ANID) (Chile)
e_Buah Biblioteca Digital Universidad de Alcalá
Publication Artículo científico (JournalArticle)

Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)

  • Noureddin, Mazen
  • Truong, Emily
  • Mayo, Rebeca
  • Martínez Arranz, Ibón
  • Mincholé, Itziar
  • Banales, Jesús M.
  • Arrese, Marco
  • Cusi, Kenneth
  • Arias Loste, María Teresa
  • Bruha, Radan
  • Romero Gómez, Manuel
  • Iruzubieta, Paula
  • Aller de la Fuente, Rocío
  • Ampuero Herrojo, Javier
  • Calleja López, José Luis
  • Ibáñez Samaniego, Luis
  • Aspichueta, Patricia
  • Martín Duce, Antonio|||0000-0001-8751-9224
  • Kushner, Tatyana
  • Ortiz Remacha, Pedro Pablo
  • Harrison, Stephen A.
  • Anstee, Quentin M.
  • Crespo, Javier
  • Mato, José M.
  • Sanyal, Arun J.
14 p., La enfermedad hepática esteatósica asociada a disfunción metabólica (MASLD) constituye la enfermedad hepática crónica más frecuente (afecta al 35% de la población mundial). Su forma progresiva, la esteatohepatitis asociada a disfunción metabólica (MASH), conlleva un elevado riesgo de cirrosis, hepatocarcinoma y mortalidad. Tradicionalmente, su diagnóstico exige una biopsia hepática (técnica invasiva, costosa y con riesgo de complicaciones). En este contexto, el estudio aborda un reto crítico alineado con el ODS 3 (Salud y Bienestar): la necesidad imperiosa de desarrollar herramientas no invasivas y accesibles para la detección precoz de enfermedades no transmisibles, mitigando la iatrogenia de las biopsias y garantizando un diagnóstico equitativo que no dependa de infraestructuras hospitalarias altamente complejas (ODS 10: Reducción de las Desigualdades). OBJETIVOS DEL ESTUDIO: El objetivo principal fue desarrollar y validar un nuevo índice no invasivo, denominado Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF), destinado a identificar pacientes con riesgo de MASH con actividad inflamatoria significativa y fibrosis avanzada (NAS ?4 y fibrosis ?F2). El estudio, fuertemente vinculado al ODS 9 (Industria, Innovación e Infraestructura), buscó trasladar la innovación tecnológica (metabolómica) a la práctica clínica diaria mediante biomarcadores séricos, complementando los algoritmos actuales. APORTACIÓN METODOLÓGICA: Se desarrolló un modelo diagnóstico combinando variables clínicas y bioquímicas (IMC, AST, ALT) con la integración de 12 metabolitos lipídicos séricos. Constituyendo un claro ejemplo del ODS 17 (Alianzas para lograr los objetivos), la herramienta fue validada en una amplia cohorte internacional de 1.355 pacientes (790 de derivación y 565 de validación) procedentes de 9 países, gracias a la financiación transnacional competitiva (NIH de EE. UU. y MINECO de España). RESULTADOS: El índice MASEF demostró una excelente capacidad diagnóstica (AUROC de 0,79 en validación). Al combinarse con el índice FIB-4, mostró un rendimiento comparable al del FIB-4 asociado a elastografía de transición (FibroScan). Especialmente relevante es su elevado valor predictivo negativo (0,88), que permite descartar con alta seguridad a pacientes de bajo riesgo, evitando biopsias hepáticas innecesarias., Background: Early identification of those with NAFLD activity score ≥ 4 and significant fibrosis (≥F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH. Methods: We included derivation (n = 790) and validation (n = 565) cohorts from international tertiary centers. Patients underwent laboratory assessment and liver biopsy for metabolic dysfunction-associated steatotic liver disease. Based on 12 lipids, body mass index, aspartate aminotransferase, and alanine aminotransferase, the MASEF score was developed to identify at-risk MASH and compared to the FibroScan-AST (FAST) score. We further compared the performance of a FIB-4 + MASEF algorithm to that of FIB-4 + liver stiffness measurements (LSM) by vibration-controlled transient elastography (VCTE). Results: The diagnostic performance of the MASEF score showed an area under the receiver-operating characteristic curve, sensitivity, specificity, and positive and negative predictive values of 0.76 (95% CI 0.72-0.79), 0.69, 0.74, 0.53, and 0.85 in the derivation cohort, and 0.79 (95% CI 0.75-0.83), 0.78, 0.65, 0.48, and 0.88 in the validation cohort, while FibroScan-AST performance in the validation cohort was 0.74 (95% CI 0.68-0.79; p = 0.064), 0.58, 0.79, 0.67, and 0.73, respectively. FIB-4+MASEF showed similar overall performance compared with FIB-4 + LSM by VCTE ( p = 0.69) to identify at-risk MASH. Conclusion: MASEF is a promising diagnostic tool for the assessment of at-risk MASH. It could be used alternatively to LSM by VCTE in the algorithm that is currently recommended by several guidance publications., Fondo Nacional de Ciencia y Tecnología de Chile (FONDECYT), The Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS)